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Abstract
Overexpression of a RHAMM isoform (RHAMMΔ163) transforms fibroblasts but the
mechanisms underlying this oncogenic function are not well understood. RHAMMΔ163 binds
to the mitotic spindle and centrosomes via a C-terminal leucine zipper; these interactions are
predicted to regulate genomic stability and cell polarity and proposed to account for the
oncogenic function of RHAMMΔ163. We hypothesized that RHAMM leucine zipper
maintains mitotic spindle integrity and impacts directional cell migration through its
interactions with microtubule and centrosome structures. The consequences of a mutated
leucine zipper on cell division, cell motility, and tumorigenesis were assessed. Although
mutant RHAMMΔ163 promoted polycentrosomy, it did not alter cell cycle progression and did
not strongly affect proliferation or tumorigenesis. However, loss of the leucine zipper
function blocked directional movement of fibroblasts without affecting rate of motility.
These results suggest that the RHAMM leucine zipper selectively regulates directed
migration, which is a centrosome function that contributes to tumorigenesis.
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Chapter 1

1

Introduction

Constant cell turnover is required for the maintenance of cellular homeostasis and
requires a delicate balance between mitogenic growth signals that regulate cell
proliferation and anti-proliferative signals that help mediate cell death (1, 2). Protooncogenes and tumor suppressors, in part, maintain this regulation. Whereas protooncogenes, like Ras and c-Src, are essential for proper cell growth, proliferation,
migration and differentiation, tumor suppressors, such as the retinoblastoma protein, Rb,
and the transcription factor, p53, repress the cell cycle and promote cellular apoptosis to
prevent aberrant cell growth (3). Mutations in these regulatory pathways that disrupt
homeostasis, not surprisingly, result in the progression of diseases such as cancer. Cells
ignore regulatory cues that normally inhibit cell cycle progression thereby promoting
tumor growth (3). Strict regulation of the mechanisms that govern cell division must
therefore be tightly regulated.

1.1 Regulation of mitotic cell division

Two main steps characterize cell division: DNA replication during interphase and then
the subsequent separation of replicated chromosomes into two daughter cells during
mitosis (4). Interphase is comprised up of three phases: G1, S, and G2, whereby a cell

2

prepares for DNA replication (G1), replicates its DNA (S), and then prepares the cell to
undergo mitosis (G2) (4). DNA replication during S phase is also linked with centrosome
replication to ensure that both DNA and centrosomes are only replicated once during
each cycle of cell division (5). Centrosome replication involves the duplication of a pair
of centrioles and their subsequent separation to spindle poles during prophase of mitosis.
Centrioles are linked together through an amorphous mass of coiled coil proteins called
the pericentriolar material (PCM) (5). These proteins are recruited to the spindle poles via
motor proteins to help carry out centrosome function (6-8). Centrosomes make up the
microtubule-organizing center (MTOC) in mammalian cells and function as a major site
for microtubule nucleation (7). They also influence a number of cellular functions such as
cell polarity and migration, establishment of a bipolar mitotic spindle, and thus proper
cell division (9).
Following DNA and centrosome replication, a cell is ready to undergo mitosis. Mitosis is
a very brief, yet highly complex and tightly regulated stage of the cell cycle. Mitotic cell
division, which is described as the division of the parent cell into two genetically
identical daughter cells, occurs in eukaryotic tissues and is critical for development and in
maintaining tissue homeostasis (10). The mitotic phase is characterized by five
consecutive stages including: prophase, metaphase, anaphase, telophase, and cytokinesis.
During this process, centrosomes migrate to opposite poles of the cell and signaling
events promote microtubule nucleation from several sources, predominately the MTOC,
but also from chromosomes (11). The microtubule network then organizes itself to form a
bipolar mitotic spindle. Microtubules emanating from centrosomes in the MTOC attach
to protein structures, referred to as kinetochores, on the chromosomes, which then aligns

3

the chromosomes midway between the two poles and aids in the separation of the sister
chromatids to each spindle pole of the developing daughter cell (12, 13).
The mitotic spindle machinery is comprised of microtubules, centrosomes, chromosomes,
molecular motors, microtubule-associated proteins, and numerous spindle assembly
protein factors that ensure spatial-temporal spindle formation (13).
Amongst other factors, Ran GTPase plays a pivotal role in mitotic spindle formation by
creating a Ran-GTP gradient around chromosomes (14, 15). Once a gradient has been
established, proteins that promote microtubule nucleation and stability are activated. One
target of Ran-GTP is TPX2 (targeting protein for Xklp2), a spindle assembly protein
factor that upon activation is released from inhibition by importin-α and initiates
microtubule nucleation and activation of downstream targets like Aurora kinase A
(AURKA) (16). AURKA is a mitotic serine/threonine kinase that is predominantly
activated by TPX2 and whose role is to phosphorylate key proteins to facilitate in the
organization of a bipolar spindle (17). Not surprisingly, inhibition of Ran activity results
in aberrant mitotic spindles and chromosomal abnormalities (18). Furthermore, molecular
motors like dynein, walk along microtubules and carry spindle-associated proteins to
their minus ends to ensure proper formation, function and integrity of the mitotic spindle
(19). One example of a spindle-associated protein is the receptor for hyaluronan-mediated
motility, RHAMM. RHAMM associates with dynein at the spindle poles and it functions
to ensure the formation of a bipolar spindle (19). The mechanism by which RHAMM
regulates mitotic spindle assembly is not fully understood, however, its genetic deletion
results in mitotic defects characterized by multipolar mitotic spindles (20).
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Cells employ additional checkpoint mechanisms during spindle assembly to monitor and
regulate proper spindle formation. Assembly of the mitotic spindle is controlled by two
linked checkpoints: the kinetochore attachment checkpoint and the spindle assembly
checkpoint (SAC). The kinetochore attachment checkpoint ensures that all chromosomes
are stably attached by their kinetochores to mitotic spindle microtubules from either
spindle pole (21). The cell then relays the status of the kinetochore-microtubule
attachment to the SAC. If all chromosomes are attached properly to the spindle poles,
chromosome segregation commences. If, however, chromosomes are not attached
properly, it signals the intact SAC to halt the cell cycle and delay anaphase until all
chromosome kinetochores are properly attached to the microtubule spindles (22). Failure
to attach can lead to chromosomal missegregation and thus this regulatory mechanism is
essential in maintaining genomic stability within a cell. When proteins that regulate the
SAC become mutated, the fidelity of chromosome segregation becomes compromised as
the SAC becomes defective and cells ignore the checkpoint and continue cell division
(22, 23). Segregation defects can result in a gain or loss of part or whole chromosomes
leading to chromosomal instability, which is a major driving force in cancer
progression(10). Changes to chromosome number can result in a state of aneuploidy and
changes to chromosome structure can lead to loss or translocation of critical genomic
DNA, both contributing to genomic instability, which then has the potential to drive these
premalignant cells cancerous (22).
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1.2 Cancer Development

Cancer development is a complex, multi-step process that arises as a result of multiple
genetic alterations that drive the transformation of normal cells to malignant cancer cells.
During cancer initiation, oncogenes become hyperactivated and acquire gain-of-function
mutations, whereas mutations in tumor suppressors accumulate and cause their loss-offunction (24, 25). These mutations give rise to numerous types of human cancers all
governed by disruption of a subset of key cellular processes. Hanahan and Weinberg (26)
identified several key hallmarks of cancer that promote a cell’s progression from a
normal state to a malignant transformed phenotype. Based on this, a cancer cell must
initially acquire the ability to autonomously grow, resist anti-growth cues, and ignore
signals for programmed cell death (26).
Cells normally require mitogenic factors that bind to their respective receptors and
stimulate a signaling cascade to promote cell proliferation. Conversely, transforming cells
do not rely on exogenous growth signals to propagate, but rather have the ability to
synthesize their own mitogenic factors to sustain their proliferation(26). Furthermore,
these cells overexpress cell surface receptors that become overly responsive to growth
factors and this results in a deregulation of downstream signaling pathways, such as that
of the mitogenic Ras-Raf-MAP kinase cascade(26). Cancer cells may acquire mutations
that induce constitutive expression of the Ras oncogene and enables them to bypass
signaling through their upstream receptors (27).
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Tumor cell proliferation is often linked with resistance to anti-growth signals that is
otherwise associated with normal cells. Normal cells receive cues from their environment
to halt the cell cycle and enter a state of quiescence in G0 or enter into a post-mitotic state
in order to maintain homeostasis (26). This regulation is achieved through tumor
suppressors such as Rb and p53 (26, 28, 29). Rb helps to regulate cell cycle progression
and apoptosis by controlling the function of E2F transcription factors and thus the
progression from G1 to S phase of the cell cycle (30). p53 is essential during the DNA
damage response in cells and arrests the cell cycle or initiates apoptosis if the damage
cannot be repaired (28). When mutated or inactivated, these tumor suppressors lose their
function and cells are not able to respond to anti-growth signals, thus promoting
tumorigenesis.
Not only do cancer cells resist anti-growth cues, but also become insensitive to signals
promoting programmed cell death, which in turn disrupt cell homeostasis. Signals that
typically activate the apoptotic machinery include defects in cell division, either DNA
replication or during mitosis as well as cellular stresses arising from DNA damage,
accumulation of ROS species, or hypoxia (26). Conversely, cancer cells acquire
mechanisms to evade apoptosis by up-regulation of anti-apoptotic factors, such as Bcl-2,
or by inactivation of the tumor suppressor p53 (26, 31). This attribute allows cancer cells
to thrive and become resistant to cancer therapies (26).
While these hallmarks are all critical for the primary transformation of normal cells into
malignant phenotypes, arguably the deadliest characteristic of cancer cells, which
accounts for more than half of cancer related deaths (32), is their ability to metastasize to
distant tissues and form secondary lesions. In order to metastasize, cancer cells acquire
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increased migration and invasion abilities. Therefore, the events regulating cell migration
and invasion must be finely tuned to prevent triggering a cell’s metastatic potential.

1.3 Cell Migration

Cell migration is essential during many cellular processes including embryogenesis,
tissue regeneration, wound healing, and immune surveillance (33, 34). Migratory events
are generally tightly regulated and when they are perturbed can play a causative role in
numerous diseases such as chronic inflammation, autoimmune diseases, and tumor
progression and metastasis (35-37).
Several biochemical pathways are involved in the initiation of cell migration and are
predominantly regulated by the Rho family GTPases, including Rac1, Cdc42, and RhoA
(34, 36). The Rho family of GTPases is a subset of the Ras superfamily and these
proteins play a vital role in cell migration by regulating the actin network, microtubule
dynamics, and several signal transduction pathways (33, 35, 38, 39). They function as
molecular switches cycling between an inactive GDP-bound form, where they reside in
the cytosol, and upon activation to their GTP-form they translocate to specific
membranes or the actin cytoskeleton where they interact with target proteins and generate
a downstream signal (33, 34).
During cell migration, specific Rho family GTPases, Cdc42 and Rac1, interact with their
targets and first polarize the cell and orient it towards the migration front end (34).
Activated Cdc42 and Rac1 stimulate actin polymerization to form finger-like projections
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or protrusions, filopodia and lamellipodia, respectively, at the leading edge which are
used to establish stable adhesions to the substratum (33-35). To initiate cell migration,
RhoA regulates the assembly of actin and myosin bundles, which facilitate the
contraction of the cell body and the rear end of a cell to detach rear adhesions and
translocate toward the leading edge (40). Migratory events require adhesion sites at the
leading and rear end of the cell to alternatively assemble and disassemble via actin
reorganization in a spatiotemporal manner to propel a migratory cell forward (33-35).
The role of microtubules during cell motility is not well established, but a dynamic
microtubule network is required (40). Microtubules are present in both the leading and
trailing edges, but are more dynamic at their tails. Inhibition of microtubule dynamics
blocks cell migration due to an inability of cells to retract their trailing edges (40). Loss
of the microtubule network via treatment of cells with high concentrations of nocodazole
inhibits directional cell migration and as a result cells move more randomly (40).
Directed cell migration depends on the polarization of microtubules and the reorientation
of the MTOC towards the direction of migration. During migration, microtubules
function as tracks for motor proteins to transport cellular cargo towards the leading edge
and for regulating cell polarity and shape (41). Microtubule minus ends emanate from the
MTOC, where they are nucleated from and are dynamically unstable at their plus ends.
Stabilization of the plus ends during cell migration enables the MTOC to reorient itself
towards the direction of migration at the leading edge (33, 41). The major component of
the MTOC is the centrosome and centrosomes are known to play an integral role in cell
polarization as its damage/loss disrupts directed motility (42). Regulation of these
pathways are dependent on Rho GTPases, particularly Cdc42, which acts through its
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effectors to control the position of the nucleus relative to the MTOC and also plays a role
in microtubule orientation (34, 38).
De-regulation of migratory pathways is seen in a number of metastatic cancers. Cell
migration of cancer cells is augmented via communication between the cell and its local
microenvironment, which constitutes the extracellular matrix (ECM) and other cells such
as stromal cells, fibroblasts, and immune cells (39, 41, 42). These cells begin to
overexpress growth factors and chemokines, which bind to cancer cell receptors and elicit
pro-migratory pathways (43, 44). An enhanced migratory ability allows cancer cells to
invade into the ECM and local microenvironment and travel on ECM fibers to blood
vessels. Carcinoma cells then intravasate into the blood stream where they travel via the
vasculature to distant sites, extravasate and form secondary tumors (43).

1.4 Extracellular Matrix

The ECM is an intricate network of macromolecules that provides structural and
functional support to the surrounding cells within a tissue (38, 45). Cells interact with the
ECM through the integrin family of transmembrane receptors as well as other cell surface
receptors, such as RHAMM (46-48). The attachment of these cell receptors to the ECM
elicit a variety of biochemical signal transduction pathways that in turn regulate
numerous cellular functions including, cell growth, migration, differentiation, and
maintaining tissue homeostasis (47). Abnormalities in ECM proteins are seen in a wide
variety of human diseases (49). In particular, aberrations in ECM components give
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cancer cells the ability to promote tumor proliferation, migration and invasion. As well,
deregulation of the ECM components impacts the surrounding cells in the local
microenvironment, including stromal cells, immune cells, and fibroblasts, and together
help promote disease progression (48, 50, 51). Therefore, understanding the role of ECM
proteins and how they affect signaling pathways can provide insight into how cancer is
initiated.
Two main classes of macromolecules make up the ECM: fibrous proteins and
glycosaminoglycans (GAG). Fibrous proteins present in the ECM include collagen,
fibronectin, and elastin, just to name a few, and they help to maintain the ECM’s
structure by providing tensile strength, protecting against stretches in the tissue, and in
mediating cell adhesion to the ECM (45). Conversely, GAGs are large, extremely
hydrophilic polysaccharides and their ability to form hydrogels serves an essential role in
resisting compressive forces (45). GAGs have a wide variety of other functions that are
molecule and tissue-specific.

1.4.1

Hyaluronan

One GAG of interest, hyaluronic acid/hyaluronan (HA), is found widely distributed
throughout the ECM of all vertebrates. Its negative charge at neutral pH and hydrophilic
nature attracts water molecules within the ECM, giving it an essential lubrication and
hydration function(52). HA is a high molecular weight GAG with an average molecular
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mass of 4x106 Da and it is composed of alternating disaccharide units of D-glucuronic
acid and D-N-acetylglucosamine (53, 54).
Hyaluronan is synthesized by hyaluronan synthases (HASes), of which there are three
conserved genes—HAS1, HAS2, HAS3—each with a unique spatial and temporal
expression pattern (52). During embryonic development, HAS2 synthesizes the majority
of hyaluronan present (52) and its expression is also unregulated during tumor
progression in a number of cancers, including breast cancer, mesothelioma, and colon
cancer (52, 55-57).
Conversely, hyaluronan is degraded by a number of hyaluronidases (HYALs), with the
two most prominent HYALs being HYAL1 and HYAL2. Aberrant expression of either
has been seen in invasive ductal carcinoma (52, 58, 59).
Hyaluronan also functions as a signaling molecule in a number of cellular processes
including cell migration, proliferation, and during wound healing (52). In particular, HA
synthesis is consistently and transiently increased immediately after tissue injury and in
sites of rapid tissue turnover, including embryogenesis, inflammation, and neoplasia (52).
The vast functions of HA are dependent on its molecular weight (48)—degradation of
HA gives rise to bioactive molecules that function differently than full-length forms. For
example, full-length hyaluronan is antiangiogenic and immunosuppressive, whereas
hyaluronan fragments promote angiogenesis and inflammation (48, 60-62).
HA mediates its effects through interactions with a class of proteins referred to as the
hyaladherins. This class of hyaluronan-binding proteins differs in their cellular
distribution, either within subcellular compartments or on the cell surface, and the
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sequences by which they interact with HA and thus the effects they exert are hyaladherinspecific (63). One hyaladherin of interest is RHAMM, which interacts with HA both
intracellularly and at the cell surface and their interactions regulate a number of cellular
functions including cell proliferation and cell migration (64, 65).

1.5 RHAMM structure and function

RHAMM was first isolated and purified from subconfluent migrating cardiac fibroblasts
as a cell surface hyaluronan binding protein (66, 67). It is largely an acidic coiled-coil
protein with a basic amino-terminal globular head (68, 69). RHAMM binds to hyaluronan
via two carboxyl terminal coiled domains that are rich in basic amino acids and are
commonly referred to as B(X)7B motifs (70, 71). This region partially overlaps with one
of two microtubule-binding sites of RHAMM—an N-terminal sequence for associating
with interphase microtubules and a C-terminal binding region for interacting with mitotic
spindle microtubules, the latter of which overlaps with the HA binding site (20, 69).
RHAMM also contains a highly conserved D-docking site common to many ERK
binding substrates (Figure 1.1B) (20).
RHAMM protein contains a number of leucine zipper domains and along with its coiled
coil structure predicts that it can form homodimers or heterodimers with its binding
partners (71, 72). One particular leucine zipper domain of interest is located within the Cterminal microtubule-binding region and this sequence presumably functions in and
regulates RHAMM and mitotic spindle interactions/integrity (Figure 1.1C) (19, 20, 73).
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RHAMM protein is found in many species and is predominantly studied in humans,
mice, and Xenopus laevis, where the protein sequences are most homologous at their Nand C-termini (74). The RHAMM gene is comprised of 18 exons and is located on
chromosome 5 in humans; its mRNA transcript encodes an 84-kDa protein (Figure 1.1 A)
(75). In mice, the RHAMM gene is localized to chromosome 11 and its mRNA transcript
encodes a 95-kDa protein. Furthermore, the RHAMM gene in Xenopus encodes a 150kDa protein and it is 45% and 65% identical to human and mouse RHAMM, respectively
(74).
RHAMM expression is tightly regulated and is absent or present at low levels in most
homeostatic human tissues. Protein and mRNA levels of RHAMM, however, are
transiently and strongly up-regulated during tissue repair (64, 76). Surprisingly, genetic
deletion of RHAMM in mice displays no visible defects during embryonic development,
albeit with slow healing of skin wounds, owing to its essential role during wound repair
(64).
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D domain for ERK binding

HA binding

Figure 1.1 Schematic Representation of RHAMM
A) The RHAMM gene is comprised of 18 exons. Exons 4 and 16 contain tubulin-binding
sequences, for binding to interphase and mitotic spindle microtubules, respectively. B)
Full-length RHAMM encodes a 794 amino acid protein sequence. RHAMMFL contains
two tubulin-binding sites, at the N-terminus and C-terminus. The C-terminal end of
RHAMM contains HA and ERK binding sites that overlap with the leucine zipper motif.
RHAMMΔ163 is an oncogenic isoform and only contains the C-terminal tubulin binding
sequence. C) Amino acid sequence of a C-terminal RHAMM fragment containing the
leucine zipper motif (highlighted in pink) with overlapping HA and ERK binding sites
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Furthermore, elevated RHAMM expression is associated with several pathologies,
including arthritis, diabetes, and several human cancers (77-81).
RHAMM is present in many cell types, including: fibroblasts, smooth muscle cells,
immune cells, and endothelial cells, just to name a few (20, 82-84).
It is a multifunctional protein with extracellular and intracellular functions that affects
cell motility/invasion and mitotic spindle integrity/genomic stability, respectively.
RHAMM is part of a heterogeneous group of cell surface proteins that lack an N-terminal
signal peptide and is therefore not exported through the classic Golgi/ER route (85). This
class of proteins is nonetheless released to the extracellular compartment via poorly
characterized unconventional export mechanisms and in response to specific stimuli (85).
For example, during cell transformation in multiple myeloma and in highly invasive
breast cancer cell lines, the putative oncogene RHAMM is unconventionally exported to
the cell surface, where it contributes to tumor formation (85, 86). Other stimuli that
induce RHAMM export include cell stress, during cell transformation or wounding (87).
Extracellular RHAMM is not integrated into the plasma membrane by membrane
spanning sequence or by GPI tail. At the cell surface, it functions as a co-receptor,
binding hyaluronan and a number of tyrosine and non-tyrosine kinase receptors,
including PDGFR, RON, CD44, and TGFβR (48, 76, 88-90).
RHAMM binding to CD44 and HA promotes cell migration through activation of the
ERK1,2 MAP kinase pathway (64). RHAMM also interacts with and mediates activation
of Src and focal adhesion kinase (FAK) and these interactions are essential for focal
adhesion turnover during cell motility (65). Furthermore, extracellular RHAMM
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regulates cell cycle progression; blocking cell surface RHAMM results in a slower
progression of cells through G2/M, a stage in the cell cycle where RHAMM mRNA is
up-regulated (91).
In addition to its localization on the cell surface, RHAMM is also present in several
subcellular compartments, where it plays a prominent role in cell proliferation events.
RHAMM localizes to the cell nucleus, on interphase microtubules, centrosomes,
podosomes, and on mitotic spindle microtubules (20, 69, 72, 85). Furthermore,
intracellular RHAMM interacts with MEK1/ERK1,2 complexes and targets them to
microtubules, where they control the stability of interphase and mitotic spindle
microtubules (20), and to the cell nucleus (20, 76), where they play a role in regulating
mitotic spindle integrity, cell cycle progression, cell proliferation, and likely centrosome
function (19, 20, 81). Deregulation of these functions not only result in defected mitotic
spindle assembly, but also disrupt centrosome structure (19, 81, 85). RHAMM-regulated
ERK activity is required for maintaining a bipolar mitotic spindle and defects due to
RHAMM loss can be rescued by mutant active MEK1 (20). The complete mechanisms
by which intracellular RHAMM carries out these functions are still being characterized.
The complex subcompartmentalization of RHAMM is not well understood, but is likely
attributed to specific targeting of isoforms within the cell. Several isoforms of RHAMM
exist in cell lines, some of which are generated via alternative mRNA splicing and others
are through alternative start codons resulting in N-terminal truncated isoforms (72, 92).
Full-length RHAMM most often localizes to microtubules, whereas targeting of
RHAMM to the nucleus requires either N-terminal truncations or alternative splicing (69,
93). The N-terminal truncated forms of RHAMM appear typically after cells are plated in
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culture as well as following tissue injury (94). One isoform, termed RHAMMΔ163, is an
N-terminal truncation of the full-length protein and represents the oncogenic form of
RHAMM found in many human cancers (95). In experimental models, overexpression of
RHAMMΔ163 transforms 10T1/2 and 3T3 mesenchymal cell lines, which form metastatic
tumors in NOD/SCID xenograft mouse models (95). The mechanisms by which
RHAMM mediates MEF transformation, however, have not been fully elucidated.
Aberrant RHAMM regulation of mitotic spindle integrity has been predicted to contribute
to tumor progression by promoting genomic instability, but neither an effect on genomic
stability or if this is relevant to progression has been directly demonstrated (73, 78). Thus
an understanding of how RHAMM is involved in the regulation of microtubule and
centrosome structures/function can help us better understand the oncogenic roles of
RHAMMΔ163.

1.6 The role of RHAMM in mitosis

1.6.1

The role of RHAMM in microtubule and mitotic spindle
regulation

The microtubule network is composed of polymers of α- and β-tubulin heterodimers that
make up one constituent of the structurally important cytoskeleton. A dynamic
microtubule network with rapid turnover is necessary for cellular events such as
formation of the mitotic spindle during mitosis. Microtubule stability is regulated in part
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by a group of microtubule-associated proteins (MAPs), including RHAMM, that bind to
tubulin and either directly or indirectly contribute to its polymerization and stability by
decreasing disassembly rate (10, 41).
Many proteins make up the microtubule-associated proteome (MTAP) and RHAMM is
one known component (96). Its functions during mitosis are dependent on its interactions
with and regulation of microtubules. Full length RHAMM consists of two conserved
microtubule-binding sequences, one located in exon 4 and the other in exon 16 (Figure
1.1A), for binding to interphase and mitotic spindle microtubules, respectively, and these
interactions are seen in numerous cell backgrounds (20, 69, 81).
The N-terminal microtubule binding sequence of RHAMM located in exon 4 is essential
for binding to interphase microtubules and deletion of this region results in a loss of
RHAMM localization from interphase microtubules and rather a diffuse distribution
throughout the cytoplasm, as well as in the cell nucleus (19, 69).
Furthermore, RHAMM is localized to microtubules throughout the mitotic phases of the
cell cycle. During prophase, in both adherent, (HeLa cells), and suspension cell lines,
(RPMI 8226 and Raji cells) RHAMM is found distributed at the center of microtubule
asters emanating from the centrosphere (81).
In prometaphase and metaphase, intracellular RHAMM localizes to mitotic spindle poles
and along the length of microtubules through a carboxyl terminal region (19).
Additionally, throughout anaphase and telophase, RHAMM is localized at the midbody
and microtubule spindles at the midzone, respectively, where it functions during
cytokinesis (19). Genetic deletion of RHAMM in fibroblasts results in aberrant
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chromosome alignment/segregation and inappropriate cell division during mitosis, giving
rise to multinucleated cells(20). Consistent with its role during cytokinesis, RHAMM has
been shown to interact with supervillin—a gelsolin family member of proteins that
functions in mysoin II mediated contractility during the early stages of cytokinesis (9799).
Although RHAMM functions throughout the stages of mitosis, it has largely been studied
for its role in organizing and maintaining mitotic spindle integrity. During cell division,
the formation of a bipolar mitotic spindle ensures fidelity of chromosome segregation and
maintains genomic stability (20). Forced high expression or genetic deletion of RHAMM
results in multi-pole mitotic spindles (19, 20, 73, 74), the former of which has been
linked to genomic instability in multiple myeloma(81). Consistent with these data, siRNA
knockdown of RHAMM in neointimal smooth muscle cells (SMCs) and HeLa cells
resulted in multipolar spindles and disorganized spindles, further confirming RHAMM’s
role in spindle assembly (84, 100). siRNA knockdown of RHAMM in HeLa cells also
resulted in a delay in spindle assembly and a delay in the time required to complete
mitosis, suggesting a role for RHAMM in microtubule nucleation (100). These defects
can collectively be rescued by re-expression of RHAMM confirming the aberrations to be
a particular result of the loss of RHAMM (19, 20, 73, 74, 100). Levels of RHAMM must
thus be tightly regulated as an abundance or loss results in aberrant mitosis.
Although the mechanism by which RHAMM regulates mitotic spindle integrity is not
well established, previous work has highlighted an important role for the highly
conserved leucine zipper located in exon 16 (19, 20, 73) in mediating RHAMM/mitotic
spindle interactions (Figure 1.1C). Previous mutational analysis of the leucine zipper
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motif demonstrated an essential role for it in maintaining spindle pole organization and
recruitment of key spindle protein factors (73, 100). Tubulin binding assays also
confirmed that RHAMM binds to tubulin heterodimers via its C-terminal domain and this
interaction can be abolished by a synthetic peptide containing the leucine zipper (20).
Furthermore, in Xenopus, binding of RHAMM to tubulin is essential for Ran-driven,
chromatin-induced (noncentrosomal) spindle assembly (73, 74) and depletion of
RHAMM results in defects in microtubule assembly (74). The latter two studies thus
suggest that tubulin and mitotic spindle binding regions of RHAMM overlap, though
direct analysis of this has not been previously published.
The C-terminal leucine zipper motif of RHAMM partially overlaps with the hyaluronan
and ERK1 binding sites (Figure 1.1C). It is therefore not surprising that RHAMM’s role
in mitotic spindle integrity is in part attributed to RHAMM’s interactions with HA and
MEK1/ERK1, 2 complexes.

1.6.1.1

RHAMM and HA interactions in mitosis

HA binds to intracellular RHAMM and has been shown to play a role in mitotic functions
(101). During mitosis, HA synthesis is increased and is present in abundance (102),
where it is found to associate with microtubules in the perinuclear area as well as more
peripherally in the cytoplasm of human arterial smooth muscle cells(101). RHAMM also
closely associates with microtubules and endogenous HA-positive vesicular structures;
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these interactions are confirmed following uptake of fluorescein-labeled HA and excess
unlabeled HA can competitively abolish the binding of HA to RHAMM (101).
HA is also found to intimately colocalize with RHAMM in and around mitotic spindle
microtubules of SMCs, both endogenously and following uptake of fluorescein-HA,
suggesting a role for both in the organization of astral and spindle microtubules. In later
stages of mitosis, HA staining is present in abundance throughout telophase and HA is
localized to the microtubules of the midbody during cytokinesis (101).
In support of RHAMM/HA interactions during mitosis, both RHAMM mRNA
expression and expression of hylauronan synthases, in particular HAS2 is elevated at the
G2/M boundary during cell cycle progression (67). Elevated HA synthesis during G2/M
is necessary for cell rounding as a result of cytoskeletal reorganization (101).
Furthermore, when HAS and RHAMM expression are inhibited, prostate cancer cell lines
arrest at mitosis (103). Given that both HA and RHAMM decorate the mitotic spindle
and that RHAMM and HAS mRNA are elevated at the G2/M boundary supports the
hypothesis that intracellular RHAMM/HA interactions play an integral, yet unclear, role
in a cell’s progression through mitosis. Studies hypothesize that these interactions are
essential for RHAMM’s role in regulating microtubule stability and spacing within a cell
(48, 101).
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1.6.1.2

RHAMM-dependent ERK regulation during mitosis

ERK decorates interphase and mitotic spindle microtubules in both non-transformed and
transformed cells (41, 104, 105) and has been shown to have an extensive effect on
microtubule stability by regulating the ability of these proteins to control tubulin
polymerization (41).
H-ras transformed cells, however, have higher levels of active ERK bound to interphase
microtubules and these microtubules are less stable—indicative of constant turnover—in
comparison to non-transformed fibroblasts. The effect of ERK regulation on these
processes is mediated by the upstream kinases Ras-Raf-MEK (41). Inhibition of ERKactivated signaling results in increased microtubule stability, which has been shown to
result in multi-pole mitotic spindles (20, 41).
RHAMM promotes interphase microtubule instability indirectly through MEK1/ERK1,2
activity (20). Overexpression of RHAMM has been shown to constitutively activate ERK
and expression of a dominant negative mutant form of RHAMM blocks activation of
ERK by mutant active Ras, thus providing a role of RHAMM in ERK regulation (88).
Intracellular RHAMM directly binds with ERK1 through a highly conserved D-docking
site, which partially overlaps with the C-terminal leucine zipper motif (20). This binding
site is common to many ERK binding substrates and contains both hydrophobic and
positively charged basic residues (106). Conversely, intracellular RHAMM indirectly
complexes to ERK2 and MEK1, as well as ERK1,2 substrates (20). Mutations in the Ddocking site of RHAMM results in a decreased binding of ERK1 in vitro and in cultured
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cells (20). Furthermore, expressing RHAMM mutated in the D-docking site in 10T1/2 Hras transformed fibroblasts resulted in decreased total cellular levels of phosphorylated
ERK1,2 (p-ERK1,2) as well as reduced detectable p-ERK1,2 from tubulin (20). In terms
of microtubule dynamics, expression of this mutant RHAMM form promoted
microtubule stability (20), as evidenced by an increase in the levels of acetylated tubulin
(20). Additionally, RHAMM regulation of microtubules through MAPKs appears to be
important in maintaining mitotic spindle formation/integrity as mitotic spindle defects
seen in RHAMM-/- fibroblasts are not only rescued by re-expression of RHAMM, but
also to a similar extent by mutant active MEK1 (20). This proposes a model in which
RHAMM functions as a scaffold protein that binds ERK1 and ERK2/MEK1 complex and
recruits them to microtubules, via RHAMM’s interactions with tubulin, to phosphorylate
and activate other microtubule associated proteins, which then regulate microtubule
dynamics/stability (Figure 1.2) (20, 107). With respect to the mitotic spindle, RHAMM
controls targeting of ERK to microtubule-associated substrates and hence an absence of
RHAMM would result in compromising spindle integrity, while overexpression of
RHAMM could sequester ERK1, 2 from its key target substrates and result in aberrant
localization/activation (107).
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Figure 1.2 RHAMM/ERK interactions in microtubule regulation
RHAMM functions as a scaffold protein, binding ERK1 directly and MEK1 indirectly,
recruiting them to microtubules, via RHAMM’s interactions with tubulin, which then
regulates microtubule dynamics/stability
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1.6.2

RHAMM and spindle assembly binding partners

Apart from microtubules, RHAMM binds to many other structures in the context of cell
division/mitosis, which in particular assist in the regulation of proper spindle assembly.
One critical organelle of interest is the centrosome. Centrosomes make up the
microtubule-organizing center and are the major sites of microtubule assembly. They are
comprised of two centrioles surrounded by an amorphous pericentriolar material (9). The
PMC is made up of numerous coiled coil proteins that are directed to centrosomes via
motor proteins and assist in microtubule nucleation (7). Given RHAMM’s role in
microtubule regulation, it is not surprising that RHAMM localizes to centrosomes and
this interaction helps to maintain both centrosome and spindle integrity during mitosis
(19). RHAMM binds to centrosomes via its conserved C-terminal leucine zipper (19) and
this association is seen in meiotic Xenopus extracts (74) and in mammalian cell lines
(19). Deletion constructs of RHAMM fusion proteins lacking the leucine zipper inhibit
the targeting of RHAMM to centrosomes (19). However, the leucine zipper alone is not
sufficient for targeting to centrosomes as GFP-tagged C-terminal RHAMM fragments of
100 amino acids containing the leucine zipper did not associate with centrosomes, but did
with spindle poles (19).
Furthermore, unregulated RHAMM expression leads to centrosome defects. Elevated
RHAMM expression in multiple myeloma plasma cells resulted in structural, but not
numerical, centrosomal abnormalities (81). Similarly, overexpression of RHAMM fivefold in RPMI 8226 cells in culture results in excess PCM volume (81). Knockdown of
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RHAMM in SMCs results in premature centrosome replication and the presence of
fragmented and detached centrosomes (84). Not surprisingly, expression of mutant
RHAMM in neointimal SMCs also resulted in less RHAMM being concentrated around
centrosomes, suggesting a critical role in maintaining division fidelity at least in
neointimal SMCs (84). Structural centrosome defects are typically seen in human cancers
as a result of aberrant mitosis that consequently contributes to genomic instability (81).
During mitosis, the division of the centrosome and its subsequent polar separation helps
assemble the critical bipolar mitotic spindle. Mutating the carboxyl terminal centrosomal
binding domain of RHAMM resulted in an increase in the number of spindle pole defects
(84). Thus RHAMM’s localization to centrosomes provides a putative mechanism by
which RHAMM regulates spindle assembly during mitosis and accordingly helps
maintain genomic stability (79).
Like many other proteins found at centrosomes, a subset of intracellular RHAMM is
targeted to centrosomes via a complex with the molecular motor protein, dynein. In
general, the dynein/dynactin motor complex is responsible for transporting cellular cargo
to microtubule minus ends (19). RHAMM antibodies bind to dynein during interphase
and a slightly higher fraction of RHAMM binds to dynein in mitotic Xenopus extracts
(19). Co-localization studies also confirm the interaction between endogenous RHAMM
with dynein in mammalian mitotic HeLa cells (19) and neointimal SMCs, particularly at
the spindle poles and co-immunoprecipitation studies reveal that they are part of a
complex (84). Whether this interaction with dynein is direct or indirect remains unknown,
but RHAMM’s association with dynein at the spindle poles is essential in maintaining

27

mitotic spindle organization and also helps orient the mitotic spindle during metaphase
(19, 84, 93, 100).
Consistent with RHAMM’s role in maintaining spindle integrity, the carboxyl terminal
leucine zipper of RHAMM shares 72 percent structural homology with that of the
Kinesin-like protein 2 (Klp2) family (19). Klp2 proteins are plus-end associated kinesinlike proteins whose leucine zipper domain is responsible for localizing to centrosomes via
an indirect interaction with the dynein/dynactin motor complex(108). Xklp2, the Xenopus
laevis Klp2 member, is crucial for the polar separation of centrosomes and in maintaining
spindle bipolarity (19, 108) and functions via its interactions with targeting protein for
Xklp2, TPX2 (108). TPX2 is a spindle assembly protein factor that assists in microtubule
nucleation and assembly by activating AURKA, which recruits a number of key proteins
required for mitotic spindle formation (74, 81, 84, 100, 109). The structural similarities
between RHAMM and the Klp2 family of proteins would suggest that RHAMM
functions in a similar manner to maintain spindle assembly and integrity. Not
surprisingly, TPX2 is one binding partner of RHAMM. These interactions are cell cycle
dependent and the majority of RHAMM, at least 40-60%, associates with TPX2 during
mitosis in human cells (81, 100, 110). There is no evidence in the literature to suggest
that these proteins interact with each other at other times during the cell cycle.
RHAMM’s interaction with TPX2 is essential for targeting TPX2 to the spindle poles and
activation of AURKA during spindle formation (100). Immunodepletion of RHAMM in
Xenopus meiotic cell extracts or siRNA knockdown of RHAMM in mitotic HeLa cells
both results in the loss of TPX2 at the spindle poles (74, 100). RHAMM binds to TPX2
via its conserved carboxy terminal leucine zipper region and this interaction is observed
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in many cell types, including both Xenopus and human cells (19, 74). Mutation of the
three leucines in the leucine zipper sequence to arginines abolishes TPX2 binding to
RHAMM (100). Furthermore, an alteration in this sequence results in aberrant spindle
formation and also disrupted localization of TPX2 in Xenopus laevis extracts and thus
impacted AURKA phosphorylation/activation (19, 74). Interestingly, RHAMM’s
interaction with TPX2 in human cementifying fibroma cells only occurs in the presence
of HA (109). Note that HA production is highest during G2/M when RHAMM and TPX2
interact, suggesting critical roles for these interactions in mitotic functions.

29

TPX2

AURKA

TPX2AURKA

3

TPX2

4

Centrosome
TPX2

2

1

Importin

Ran-GTP

RHAMM
RHAMM

3
TPX2

Dynein/
dynactin
Chromosome

Figure 1.3: Schematic representation of RHAMM function at the mitotic spindle
During mitotic spindle assembly, a (1) Ran-GTP gradient is established around
chromosomes and allows for the release of TPX2 from inhibitory importins (2). TPX2 is
free to interact with and activate AURKA (3;top), which assists in spindle pole assembly
(4). TPX2 can also form a complex with RHAMM and dynein/dynactin (3;bottom),
which travel along microtubules to recruit TPX2 and RHAMM to the spindle poles and
centrosomes where they both play a role in regulating mitotic spindle integrity (4)
(Adapted from Maxwell et al 2008 (85))
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1.6.3

RHAMM and cell cycle progression

Consistent with RHAMM’s role during mitosis, RHAMM expression in mammalian cells
is tightly regulated during the cell cycle, both in vitro and in vivo (79).
Quantitative real-time PCR analysis of cultured HeLa cells synchronized at the G1/S
phase and released from the block at various times after showed that the level of human
RHAMM transcripts was predominantly activated at G2/M (79). This induction of
RHAMM expression at the G2/M phase of the cell cycle coincides with the expression of
a hallmark G2/M regulatory protein, cyclin B (79). Briefly, cyclin B expression is cell
cycle regulated, its expression peaks during mitosis, and it is necessary for cells to
progress through mitosis by forming a complex with the regulatory cyclin dependent
kinase 1 (Cdk1) (4).
RHAMM expression is also elevated at G2/M in vivo in the liver of BALB/c mice that
were subjected to a 70% partial hepatectomy (79). Generally, the liver is a highly
differentiated organ and is not a suitable for examining cell division except in the case
where a hepatectomy was subjected where the regeneration of a liver exhibits normal cell
cycle regulated gene expression. BALB/c mice showed elevated RHAMM expression
after 48 hours during liver regeneration and this coincided with cyclin B expression at the
G2/M phase (79).
In line with these findings, Sohr et al (111) demonstrated that expression of both
RHAMM mRNA and proteins are cell cycle regulated in human foreskin fibroblasts
(HFF). Whereas RHAMM mRNA and protein follow the same expression patterns in the
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early stages of the cell cycle, mRNA expression peaks at G2/M, however, protein levels
peak and begin to decrease during S phase of the cell cycle (111).
Consistent with RHAMM’s role in G2/M regulation, ectopic overexpression of RHAMM
in human 293T cells results in the accumulation of a population of cells in G2/M as
demonstrated by FACs analysis (79). This suggests that overexpression of RHAMM
affects cell cycle G2/M progression by arresting cells during mitosis. Similarly,
overexpression of GFP-RHAMM in RPMI 8226 and HeLa cells results in a metaphase
block during mitosis and a significant decrease in the number of mitotic cells (19, 81).
Conversely, the knockdown of RHAMM in HCF cells results in a decrease in the
percentage of cells at G2/M, as detected by flow cytometry (109). These results suggest
that a tight regulation of RHAMM expression levels is essential for normal cell cycle
progression.
Not surprisingly, RHAMM mRNA and protein levels are indirectly downregulated by the
tumor suppressor, p53 (48). p53 is a transcription factor that controls the expression
patterns of many genes involved in cell-cycle regulation and apoptosis. Furthermore, the
levels of many cell cycle regulators are controlled by degradation through ubiquitin E3
ligases (112). The anaphase-promoting complex (APC) is one ubiquitin ligase that helps
regulate the turnover of several spindle assembly factors, including RHAMM (113). This
regulatory mechanism appears to be important in keeping RHAMM levels in check for
binding to other spindle assembly factors, like TPX2, and promoting proper spindle
assembly (107, 113). RHAMM levels are also presumably regulated by ubiqutination
through a complex with another ubiquitin E3 ligase, BRCA1/BARD1 and this interaction
helps to keep RHAMM levels in check to maintain a bipolar mitotic spindle (73).
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The precise reason why and when cells need RHAMM for the progression of the cell
cycle are not yet clear, however, RHAMM functions in this process are likely dependent
on its interaction with, and regulation of, microtubules and centrosomes and thus its role
in maintaining mitotic spindle and centrosome integrity.
It is surprising, however, given RHAMM’s functions in these processes, that RHAMM-/mice are not embryonic lethal and there are no obvious defects in these viable mice (76).
This suggests that there are redundant mechanisms that help compensate for RHAMM
loss and perhaps RHAMM is not compensated for only during specific pathologies such
as wound repair and cancer progression.

1.7 RHAMM and cell proliferation

Given RHAMM’s interactions with cytoskeletal elements and proteins that are involved
in regulating mitosis, it is not surprising that RHAMM functions during cell proliferation.
This role, however, is often non-essential and largely cell type specific.
RHAMM promotes cell growth in several cell backgrounds via phosphorylation and
activation of ERK1/2 kinases (114). RHAMM loss in J82 bladder cancer cells resulted in
reduced cell proliferation and an increase in the percentage of cells in G1 of the cell cycle
as a result of their anti-proliferative effects; this was not due to an increase in cell death
as no induction of apoptosis was observed after RHAMM knockdown (115).
Furthermore, knockdown of RHAMM by siRNA in immortalized human cementifying
fibroma cells from the jawbone resulted in a decrease in cell proliferation and an
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inhibition of ERK1,2 phosphorylation (109). Consistent with these results, RHAMM
overexpression in MC3T3-E1 osteoblast cell line promotes cell proliferation and induces
ERK1,2 phosphorylation directly. Inhibiting activation of ERK1, 2 by using an inhibitor,
PD98059, resulted in a decrease in cell proliferation of MC3T3-E1 RHAMM
overexpressing cells (114). Similarly, blocking RHAMM function with an anti-RHAMM
antibody abolished cell growth of Kv562 human leukemic cells (116). The effects of
proliferation on these cells were mediated through RHAMM and were dependent on the
presence of HA and activation of the PI3K pathway (116).
Conversely, pancreatic islet tumor N134 cells ectopically expressing RHAMM showed
that RHAMM promotes tumor growth independent of cell proliferation(117). Staining of
uninfected cells and RHAMM-expressing tumor cells with a proliferation marker, Ki67,
demonstrated that RHAMM-expressing cells were less proliferative than controls
suggesting an inhibitory affect of RHAMM overexpression on cell growth (117).
In certain cell backgrounds, however, RHAMM was shown to have no effect on cell
proliferation. Overexpression of RHAMM is known to promote breast cancer progression
(94, 118). RHAMM knockdown studies in an aggressive breast cancer cell line, MDAMB-231 show no effect of RHAMM loss on cell proliferation, however, it does inhibit
cell migration and invasion (119). This suggests that RHAMM functions in breast cancer
progression is unrelated to cell proliferation, but rather is essential during migration and
invasion. Likewise, stable expression of shRNA to RHAMM in 2884 malignant
peripheral nerve sheath tumor (MPNST) cell line had no effect on cell proliferation in
comparison to controls (120).
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Taken together, this data suggests that RHAMM’s role during cell proliferation is context
and cell type dependent.

1.8 RHAMM and cell migration

Given RHAMM’s role in regulation of microtubule structures and centrosomes, it is not
surprising that RHAMM also plays an essential role during non-mitotic functions, such as
cell motility. Similar to its role in mitosis, RHAMM functions during cell migration are
mediated by its interactions with its binding partners, including ERK1,2, HA, and
centrosomes.
ERK1,2 signaling pathway has been shown to play extensive roles during cell migration
and in regulating cell protrusion, both initiation and speed (64, 121). RHAMM is
required to sustain activation of ERK1,2 and thus its localization and function (88).
RHAMM-/- fibroblasts exhibit defects in cell migration characterized by failure to
resurface scratch wounds due to slower speeds and loss of directionality compared to
RHAMM expressing fibroblasts, and these effects have been shown to be due to loss of
ERK activation (64). Genetic deletion of RHAMM also resulted in decreased activation
of ERK1,2 in the nucleus and cell lamellae, which is required for cell protrusion (64).
Defects in ERK1,2 activity and cell migration can be rescued by expression of full length
RHAMM or by an activated form of MEK1. Consistently, a MEK inhibitor blocks
serum-induced motility of RHAMM expressing fibroblasts (64). These results

35

collectively suggest a role for RHAMM-MEK/ERK interactions in regulating cell
migration.
RHAMM/HA interactions also play a role in directing cell migration of both transformed
and non-transformed cells including endothelial cells and bovine aortic SMCs (122, 123).
HA stimulation increases cell migration of ras transformed fibroblasts and arterial
smooth muscle cells (ASMCs) in a dose dependent manner and this effect is independent
of cell proliferation (122, 123). Cell migration in HA-induced ASMCs is dependent on
RHAMM as knockdown of RHAMM via siRNA inhibits cell motility. Mutation of the
HA-binding site of RHAMM also reverted the Ras-induced transformation of 10T1/2
fibroblasts (95). Furthermore, studies using RHAMM function blocking antibodies have
inhibited HA-stimulated motility in a number of cell lines (64, 67). RHAMM/HA
interactions also mediate activation of Rac1 via a PI3K dependent mechanism, which
promote the formation of actin rich lamellipodia and stress fibers that promote membrane
protrusions and contraction, respectively, during cell motility (123).
Furthermore, centrosomes are known to play an integral role during cell migration as they
help polarize the cytoskeleton (84). Centrosome loss or damage disrupts directed cell
motility due to loss of cell polarization (42), and thus strict control of the number,
structure, and position of the centrosome is critical. RHAMM localizes to centrosomes
via a carboxyl terminal leucine zipper domain (19). RHAMM plays a role in controlling
the position and function of centrosomes and accurate rear polarization during cell
migration in neointimal smooth muscle cells (SMCs) (124), the latter of which is
dependent on PKCα activity (124). Silencing of RHAMM via siRNA treatment in
neointimal SMCs results in a shift from rear polarization to front polarization of the
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MTOC and slow migrating cells compared to control treated cells (slow closing of the
scratch wound) (124). RHAMM also plays a role in the organization of the actin and
microtubule network during cell migration; silencing of RHAMM results in fragmented
lamellipodia and an increase in the number of stable microtubules in the perinuclear
region (124). Dynamic microtubules are required for cell locomotion as they assist in the
retraction of the rear end of the cell (40). Furthermore, removal of the centrosome from a
polarized cell results in changes in the actin and microtubule cytoskeletal networks,
which give rise to a non-polarized phenotype (42). These results suggest that RHAMM
plays a role in regulating centrosome function during cell migration via organization of
cytoskeletal components to give rise to a polarized cell. These results further hypothesize
that RHAMM regulation of centrosome function could attribute to the defects seen in
migration in RHAMM-/- fibroblasts (64).

1.9 The role of RHAMM in cancer

RHAMM overexpression has been implicated in a number of human cancers, including
breast cancer, multiple myeloma, prostate cancer, hepatocellular carcinomas, colorectal
cancer, ovarian cancer, and acute myeloid leukemia (79, 92, 118, 125-128). RHAMM is a
novel breast cancer susceptibility gene and high protein and mRNA expression of
RHAMM have been correlated with increased peripheral metastasis and poor outcome in
breast cancer patients (118).
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In experimental models, RHAMM overexpression is required for maintaining Ras
transformation through an HA dependent manner. Mutation of the HA binding region of
RHAMM reverts H-ras transformation (95) suggesting that RHAMM effects on
transformation are in part mediated through HA. As well, overexpression of RHAMMΔ163
isoform transforms 10T1/2 mesenchymal cell lines and these form metastatic tumors in
xenograft models, strongly suggesting that RHAMM is an oncogene (95). Consistent
with its oncogenic potential, RHAMM mRNA and protein levels are downregulated by
the tumor suppressor, p53 (48).
RHAMM functions during tumorigeneis, however, are not fully elucidated. This is in part
due to the multifunctional roles of RHAMM regulation on the cell surface and within
intracellular compartments and both play a role in cancer progression.
Cell surface RHAMM functions as a co-receptor for CD44 and upon binding hyaluronan
mediates sustained activation of ERK1,2 kinase in MDA-MB-231 breast cancer cell lines
(94). HA-dependent ERK activation results in increased cell migration and invasion,
contributing to the oncogenic effects of this protein (94).
Intracellular RHAMM regulation of mitotic spindle integrity and centrosome function
provides a putative mechanism by which RHAMM overexpression promotes genomic
instability and contributes to tumorigenesis. Consistent with this hypothesis, unregulated
RHAMM expression has been shown to correlate with genomic instability in multiple
myeloma (92)
Furthermore, RHAMM functions in mitotic spindle integrity are regulated in part by the
BRCA1/BARD1 complex (73, 78). RHAMM and BRCA1/BARD1 interactions are seen
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in numerous mammalian cell lines and together they regulate centrosome amplification
(78). BRCA1/BARD1 complex regulates the levels of RHAMM via its ubiquitin E3
ligase activity (73, 78). Overexpression of RHAMM in the absence of BRCA1/BARD1
results in disrupted mitotic spindle assembly (73).
It is well established that a loss-of-function mutation in BRCA1 increases susceptibility
to breast and ovarian cancers (78). Taken together, BRCA1 mutations along side
RHAMM overexpression thus have the potential to promote genomic instability and
contribute to breast cancer progression.

1.10 Hypotheses and Objectives

Given the importance of RHAMM in binding to and regulating mitotic spindle integrity,
microtubules, and centrosome structures, I hypothesized that RHAMM leucine zipper
maintains mitotic spindle integrity through its direct interactions with tubulin
heterodimers.
Furthermore, I hypothesized that RHAMM regulation of centrosome structures controls
cell polarity and impacts directional migration via its leucine zipper motif.
The objectives for this dissertation were as follows:
1) Examine the role of the leucine zipper of RHAMM in direct binding to tubulin, in
vitro
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2) Determine the consequences of a mutated leucine zipper motif of RHAMMΔ163 on
mitotic spindle functions and tumorigenesis
3) Determine the effects of a mutated leucine zipper motif of RHAMMΔ163 on
directed cell migration and centrosome function
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Chapter 2

2

Materials and Methods

Cell culture
The 10T1/2 mouse embryonic fibroblast (MEF) cell line was purchased from American
Type Culture Collection (ATCC; Manassas, VA, USA). RHAMM knockout (-/-) primary
mouse embryonic fibroblasts (MEFs) were isolated as described by Tolg et al., 2003 and
2006 (64, 76). Cell lines were grown as monolayers in low glucose Dulbecco’s Modified
Eagle Medium (DMEM) (Wisent BioProducts, Montreal, QC, Canada) supplemented
with 10% fetal bovine serum (FBS) (Wisent BioProducts) and 1x antibiotic-antimycotic
(Invitrogen, Life Technologies, Burlington, ON, Canada) in a humidified atmosphere of
5% CO2 at 37°C. Cells were grown to 80% subconfluency prior to passage and were
released from tissue culture plastic with 0.25% trypsin-EDTA (Invitrogen, Life
Technologies).

RHAMMΔ163 mutant constructs
Mouse RHAMMΔ163 isoform (aa163-794) was used for this dissertation. A RHAMM Δ163
with a C-terminal leucine zipper mutation was previously constructed in our lab by
altering the three leucine amino acids in the leucine zipper region using site directed
mutagenesis. The following mutations were made: Mutation 1—L735R/L742R and
Mutation 2—L728A/L735R/L742R. Wildtype and mutant RHAMMΔ163 were amplified
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by PCR with a 5’Sal I site (FW primer: 5’
GGATCAGTCGACATGAGAGCTCTAAGCCTGGAATTGATGAACT 3’) and a 3’
Bam HI site (RV primer: 5’ CCCGGATCCTCAGCAGCAGTTTGGGTTGCC 3’) using
Phusion High Fidelity DNA polymerase (New England Biolabs, Whitby, ON, Canada) as
recommended by the manufacturer. Blunt PCR products were then purified using DNA
Gel Extraction Kit (Bio Basic Inc, Markham, ON, Canada) and cloned into pCR-Blunt
vector using Zero Blunt PCR Cloning Kit (Invitrogen, Life Technologies), as per the
manufacturer’s instructions. After enzymatic digestion of both cDNA and vector with Sal
I and Bam HI restriction enzymes (New England Biolabs), cDNA was ligated into
pHβApr-1-neo expression vector under the control of the β-actin promoter. The construct
was sequenced at Robarts Sequencing Facility (Western University, London, ON,
Canada) and transfected into 10T1/2 MEFs.

RHAMM expression in 10T1/2 and RHAMM-/- MEFs
Untagged wildtype and mutant RHAMMΔ163 constructs were transfected in 10T1/2 and
RHAMM-/- (KO) MEFs using jetPrime transfection reagent (jetPrime Polyplus, New
York, NY, USA), as per the manufacturer’s instructions. Immortalized 10T1/2 and KO
MEFs were grown in a 6-well plate to a confluency of 70-80% in DMEM supplemented
with 10% FBS and 1x antibiotic-antimycotic. The plasmid DNA was diluted with
jetPrime buffer (jetPrime Polyplus) and incubated with transfection reagent at a ratio of 3
µg DNA: 7 µl transfection reagent. The transfection mix was then slowly added to the
cells and incubated for 4 hours, after which the media was replaced and incubated
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overnight. Stable cell lines were established in 10T1/2 and KO fibroblasts by selecting
for a mixed pool of transfectants with 1-5 mg/ml G418 (Sigma-Aldrich, St. Louis, MO,
USA).

DNA isolation
Wildtype and mutant 10T1/2-RHAMMΔ163 cells were harvested by trypsin, washed twice
with PBS, and then digested overnight at 56°C at 1000rpm on a thermomixer with 18µl
of 10mg/ml proteinase K in 500 µl of lysis buffer containing 1M Tris (pH 8), 0.5M
EDTA (pH 8), 10% SDS, and 5M NaCl. After overnight incubation, the cells were
suspended thoroughly by vortexing and subsequently centrifuged for 10 min at
13000rpm. Supernatant was collected and added to a new eppendorf tube containing
500µl isopropanol to precipitate the DNA. Following thorough mixing, the cells were
centrifuged for 5 min at 13000rpm and supernatant was discarded. The DNA pellet was
washed with 500µl of 70% ethanol and then centrifuged for 5 min at 13000rpm. The
supernatant was discarded and the DNA was left to air dry at room temperature overnight
and then resuspended in 50µl ddH2O for further analysis. DNA from a sample of tumor
tissue from xenograft studies weighing ~200mg was also obtained using the same
method.

43

DNA sequencing
DNA was isolated as above and amplified by PCR using primers spanning an intron-exon
boundary to amplify ~200 bp region of exogenous RHAMM. The following RHAMM
primers were used: FW: 5’ AAACCTTTTCAGCAACTGGAT 3’ and RV: 5’
AGATCGGAGTTTTGACACCTC 3’ and PCR was carried out using Phusion High
Fidelity DNA polymerase (New England Biolabs) as recommended by the manufacturer.
PCR products were then purified using DNA Gel Extraction Kit (Bio Basic Inc.) and
cloned into pCR-Blunt vector using Zero Blunt PCR Cloning Kit (Invitrogen, Life
Technologies), as per the manufacturer’s instructions. The samples were then sent to
Robarts Sequencing Facility (Western University, London, ON, Canada) to be sequenced
using M13 forward and reverse primers.

Direct and competitive tubulin ELISA
Biotinylated and unlabeled C-terminal RHAMM peptides (aa720-750) containing the
leucine zipper, both wildtype and L735R mutant, were synthesized by CanInc Peptide
(Montreal, QC). Interactions between RHAMM peptides and >99% purified bovine α/βheterodimeric tubulin protein (Cytoskeleton, Denver, CO, USA) were detected using a
direct and competitive tubulin ELISA assay (Figure 2.1). Wells of a 96-well microplate
(non-TC treated) (Sigma-Aldrich) were coated with 10 µg/ml of α/β-heterodimeric
tubulin protein (Cytoskeleton) diluted in PBS overnight at 4°C. Control wells with no
tubulin were coated with PBS. Wells were washed 3-10 minutes with 0.01% Tween-20 in
PBS and blocked with 5% skim milk in PBS for 2 hours at room temperature. After
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washing 3 times with 0.01% Tween-20 in PBS, wells were incubated with 5-40 µg/ml of
either wildtype or L735R mutant biotinylated RHAMM peptides diluted in sterile dH2O
for 2 hours at room temperature. After two hour incubation with labeled peptides, for
competitive ELISA assay, 100 µg/ml of unlabeled wildtype RHAMM peptide (diluted in
water) was mixed into the wells containing 10 µg/ml biotinylated peptides and incubated
overnight at 4°C. After thorough washing, wells were incubated with streptavidin
conjugated with horseradish peroxidase (HRP) (Abcam, Cambridge, MA, USA), diluted
at 1:2000 in PBS for 1 hour at room temperature. Wells were washed for a final 3-10 min
with 0.01% Tween-20 in PBS and the interaction was detected by incubation with 1STEP ABTS (2,2'-azinobis [3-ethylbenzthiazoline-6-sulfonic acid] diammonium salt)
solution (Thermo Scientific, Waltham, MA, USA) for 20 min, as per the manufacturer’s
instructions. The reaction was halted by the addition of 1% SDS and absorbance readings
were measured at 405 nm using the Wallac 1420 VICTOR2 plate reader (PerkinElmer,
Waltham, MA, USA). Three biological replicates were used per treatment. Control wells
with no tubulin and no peptide served as the background control.
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Figure 2.1: Direct tubulin ELISA-assay
Schematic representation of the novel tubulin ELISA assay generated for testing direct
RHAMM peptide and tubulin interactions in vitro. Wells were coated with 10µg/ml of
tubulin heterodimers and incubated with biotinylated RHAMM peptides, either wildtype
or mutant. Binding was detected via direct interactions between biotin and streptavidin,
the latter of which is HRP conjugated to allow for the subsequent enzymatic conversion
of ABTS substrate into a measurable fluorescent product
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RNA isolation
10T1/2 parental fibroblasts, as well as stably transfected wildtype and mutant
RHAMMΔ163-fibroblasts were plated on 10 cm tissue culture plastic in DMEM
supplemented with 10% FBS. When plates reached 80% subconfluency, total RNA was
isolated from cells using TRIzol Reagent (Invitrogen, Life Technologies) as per the
manufacturer’s instructions, and RNA concentrations were determined by absorbance at
260nm.Three biological replicates were used.

cDNA synthesis and quantitative real-time PCR
Quantitative real-time PCR (qRT-PCR) was used to verify the overexpression of
wildtype and mutant RHAMMΔ163 that are stably expressed in 10T1/2 fibroblasts. 1 µg of
total RNA was used to prepare a 20µl reaction volume of cDNA using Random Primers
(Invitrogen, Life Technologies) in a first strand cDNA synthesis reaction using
Superscript II Reverse Transcriptase (Invitrogen, Life Technologies) as per the
manufacturer’s instructions. Primers for qPCR were designed to amplify a 200 bp region
of mouse RHAMM and were synthesized by Invitrogen (Pleasanton, CA, USA) and
amplification of 28S RNA was used for normalization. The following primers were used:
RHAMM FW: 5’ GTTTCAATAGAGAAAGAAAAGATC 3’; RHAMM RV: 5’
CCTCAAGAGACTGCTTAAGAC 3’; 28S FW: 5’ TCATCAGACCCCAGAAAAGG
3;; 28S RV: 5’ GATTCGGCAGGTGAGTTGTT 3’. qPCR amplification was performed
on a Stratagene Mx3000P instrument (Agilent Technologies, Mississauga, ON, Canada)
with SYBR Green QRT-PCR Master Mix (Agilent Technologies) and the reactions were
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set up as per the manufacturer’s instructions provided for the master mix. The following
cycle conditions were used: 3 min at 95°C, 20 sec at 95°C, 20 sec at 60°C, 1 min at 95°C,
30 sec at 60°C, and 30 sec at 95°C. Relative expression levels were calculated by the
standard curve method and analyzed using Stratagene Mx3000P software as well as
Microsoft Excel.

Western blot of RHAMM protein expression
Parental 10T1/2 MEFs and wildtype or mutant 10T1/2- RHAMMΔ163 cells were washed
twice with cold PBS and then lysed with RIPA Buffer (Sigma-Aldrich) as per the
manufacturer’s instructions. Cells were detached from the dish with a cell scraper and
collected via centrifugation at 8000xg for 10 min at 4°C. Protein concentration from the
cell supernatant was measured using Pearson’s Modification of Micro Lowry Total
Protein Kit (Sigma-Aldrich). 10µg of protein were loaded and separated onto 10% SDSPAGE gels and transferred to a PDVF membrane (Millipore, Billerica, MA, USA).
Membrane was subsequently blocked for 1 hr at room temperature in 10% skim milk in
TBS-T (50mM Tris base pH 7.5, 150mM NaCl and 0.05% Tween-20). After washing
once with TBS-T, membrane was incubated with rabbit anti-RHAMM monoclonal
antibody (Epitomics, Burlingame, CA, USA) at a dilution of 1:500 in TBS-T containing
0.5% skim milk overnight at 4°C. Membrane was then washed 4-10 minutes with TBS-T
followed by an incubation with anti-rabbit horse radish peroxidase conjugated (HRP)
secondary antibody at a dilution of 1:100000 in TBS-T containing 0.5% skim milk for 1
hour at room temperature. After thorough 3-30min washes with TBS-T, the membrane
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was developed using the Enhanced Chemiluminescence (ECL) detection kit (GE
Healthcare, Mississauga, ON, Canada). Levels of endogenous full length RHAMM
(RHAMMFL) served as the loading control as the RHAMM antibody detects both
RHAMMFL and RHAMMΔ163 forms.

Quantification of cell proliferation
Parental 10T1/2 and KO MEFs and those stably expressing untagged wildtype or mutant
RHAMMΔ163 cells were seeded at 1000 cells/well in a 96-well plate. Cells were incubated
overnight in DMEM supplemented with 10% FBS. After 24 hours, 1/10th of alamarBlue
reagent (Invitrogen, Life Technologies) was added to wells per cell line and incubated for
5 hours in a humidified atmosphere of 5% CO2 at 37°C. Cell proliferation was assessed
over the duration of 96 hours using this method. Fluorescence readings were measured at
580nm on the Wallac 1420 VICTOR2 plate reader (PerkinElmer). Nine biological
replicates were used per cell line.

Flow cytometry
Parental 10T1/2 MEFs and 10T1/2 MEFs stably expressing wildtype and mutant
RHAMMΔ163 were seeded at 106 cells in 10 cm culture plates and allowed to adhere
overnight in DMEM supplemented with 10% FBS. Cells were released from tissue
culture plastic with 0.25% trypsin-EDTA (Invitrogen, Life Technologies) and harvested
at 1500 rpm for 5 minutes. Cell pellets were then suspended in 500 µl cold PBS and fixed
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by drop wise addition of 1.5 ml of 90% ethanol while vortexing at a slow speed setting.
After incubating fixed cells on ice for an hour, cells were centrifuged at 1500 rpm for 5
min and supernatant was discarded. Cells were then suspended in 1 ml of 2N HCl/0.5%
Triton X-100 dropwise with gentle vortexing and incubated at room temperature for 30
min. Cells were pelleted at 1500 rpm for 5 min and then resuspended in 1 ml of 0.1M
sodium tetraborate (NaB4O7) (pH 8.5). After pelleting cells at 1500 rpm for 5 min and
washing with PBS, cells were stained with 1 ml of PBS with 1% FBS and 200 µl of
1mg/ml stock of propidium iodide (Sigma-Aldrich) with 100 µl of 20mg/ml stock of
DNase-free RNase A (Invitrogen, Life Technologies) and stored overnight at 4°C.
Stained cells were detected using a flow cytometer (Beckman Coulter, Mississauga, ON,
Canada) using FACS Calibur with Cell Quest acquisition. Viable cells were gated based
on forward and side scatter (FSC and SSC, respectively) to eliminate cell debris. Cell
cycle analysis was then conducted on single cell populations at 20,000 events per sample
after gating out doublets. Analysis was performed on FlowJo software (Treestar,
Ashland, OR, USA) and percentages of cells at different stages of the cell cycle were
calculated using the Watson (Pragmatic) model on FlowJo.

Quantification of cell apoptosis
10T1/2 MEFs stably expressing wildtype and mutant RHAMMΔ163 (L735R and
L728A/L735R) were seeded at 5000 cells/well in a 96-well plate and allowed to adhere
overnight in DMEM with 10% FBS. Apoptosis was detected by the presence of monoand oligonucleosomes in the cytoplasmic fraction of cell lysates using the Cell Death
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Detection ELISAPLUS kit (Roche Applied Science, Indianapolis, IN, USA) as per the
manufacturer’s instructions. The kit detects apoptosis in cell lysates using anti-histone
and anti-DNA antibodies. Absorbance readings were measured at 405 nm using the
Wallac 1420 VICTOR2 plate reader (PerkinElmer) and four biological replicates were
used per cell lysate.

Tumor xenografts
10T1/2 MEFs stably expressing wildtype or mutant RHAMMΔ163 were seeded in tissue
culture plates to reach 80% confluency in complete DMEM supplemented with 10%
FBS. Cells were released from tissue culture plastic with 0.25% trypsin-EDTA
(Invitrogen, Life Technologies) and resuspended in complete DMEM supplemented with
10% FBS prior to cell counting via a hemocytometer. After cell counting, 2 million cells,
per mouse to be injected, were resuspended in a 50µl total volume of low glucose DMEM
with 50% volume of Matrigel Basement Membrane Matrix (BD Biosciences,
Mississauga, ON, Canada). Cells were then subcutaneously injected in the flank of 5week-old female NSG mice ordered from The Jackson Laboratory (Bar Harbor, Maine,
USA). Mice were monitored for tumor growth for 6 weeks and tumors were excised and
weighed. Three replicate mice were used per cell line to be injected.
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Cell migration
KO- RHAMMΔ163 and KO- RHAMMΔ163-L735R cells were grown to confluent
monolayers overnight in 12.5cm2 tissue culture flasks (Falcon®, VWR, Mississauga, ON,
Canada). Cell monolayers were scratched with a sterile 1250µl pipette tip and media was
replaced with fresh DMEM supplemented with 10% FBS and allowed to recover in a
humidified atmosphere of 5% CO2 at 37°C for 30 min. Wound closure was filmed on a
Nikon TE300 Inverted Microscope (Nikon, Melville, NY, USA) overnight and time-lapse
images were captured every 5 min. Number of cells that migrated in the wound postscratch were counted using ImageJ grid analysis software and the average number of
cells of three wounded areas were quantified.

Pericentrin immunofluorescence
KO MEFs and those stably expressing RHAMMΔ163 and RHAMMΔ163–L735R were
seeded to confluency at 55000 cells/well on coverslips in a 24-well plate and allowed to
attach overnight. After overnight culture, cell monolayers were scratched with a sterile
1250µl pipette tip and media was replaced with fresh DMEM supplemented with 10%
FBS and incubated in a humidified atmosphere of 5% CO2 at 37°C for 6 hours.
Coverslips were then fixed gently with fresh 3.5% paraformaldehyde for 7 min at room
temperature. After washing 3 times with 1X buffer (10X buffer: 0.1M Tris pH 7.5, 1.5M
NaCl, 1% BSA), cells were permeabilized with 0.2% Triton X-100 in 1X buffer for 5 min
at room temperature and then blocked with 1X buffer for 5 min at room temperature.
Cells were then incubated with rabbit polyclonal anti-pericentrin antibody (Abcam)

52

diluted at 1:1200 in 1X buffer for 30 min in a humidified atmosphere of 5% CO2 at 37°C.
After washing once in 1X buffer for 5 min, cells were incubated with anti-rabbit Alexa
Fluor 488 IgG diluted at 1:1000 in 1X buffer for 1 hour at room temperature. Cells were
washed once with 1X buffer and coverslips were then mounted using Prolong Gold DAPI
antifade reagent (Invitrogen, Life Technologies) and imaged on the Nikon A1R Confocal
Laser Microscope (Nikon).
The percentage of cells with greater than one centrosome at the wound edge were
quantified; mitotic figures as determined by DNA staining with DAPI, were excluded
from the count. Furthermore, the location of the centrosome relative to the cell nucleus
was determined by monitoring the directional movement of cells into the wounded area;
the percentage of cells with centrosomes behind the nucleus was quantified.

Statistical analysis
Statistical differences between groups were assessed using two-tailed Student’s t-test. Pvalues <0.05 were considered statistically significant.
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Chapter 3

3

Results

3.1 Objective 1: Examining the role of the leucine zipper
motif in RHAMM-microtubule interactions

Site directed mutagenesis of a leucine zipper interaction motif: Rationale for
mutations
Site-directed mutagenesis is routinely used to study the functional consequences of a
single, point mutation in a protein of interest. To gain a better understanding of the Cterminal leucine zipper of RHAMMΔ163, mutations were constructed by altering the
following leucine amino acid residues in the leucine zipper motif: Mutation 1—
L735R/L742R and Mutation 2—L728A/L735R/L742R (Table 3.1-Initial mutations).
Mutated RHAMMΔ163 cDNAs were prepared and cloned into the pHβ-APr1 mammalian
expression vector with a neomycin selection marker (Figure 3.1) and mutations were
confirmed by DNA sequencing. Cloned plasmids containing mutant RHAMMΔ163 cDNA
were expressed in 10T1/2 MEFs and a pool of mixed transfectants were selected in G418
to generate stable cell lines. Genomic DNA from 10T1/2 MEFs expressing mutant
RHAMMΔ163, L735R/L742R or L728A/L735R/L742R, were isolated and sequenced.
Sequencing results of both mutants revealed a R742L reversion (Table 3.1-Reverted
mutations) suggesting that this leucine residue is functionally important, yet its
significance warrants further investigation. Despite the apparent reversion under selection
pressure, mutation of one hydrophobic leucine residue to a charged arginine residue

54

should be sufficient to abolish leucine zipper dimerization function. Since stable cell lines
express the reverted sequences, experiments throughout this dissertation were based on
the reverted RHAMM mutations and referred to as L735R and L728A/L735R.

Table 3.1: RHAMM Leucine Zipper Sequences
728

Wildtype Sequence

LKDENSQLKSEVSKL 742

L735R/L742Rà

728

LKDENSQRKSEVSKR 742

Initial Mutations
L728A/L735R/L743Rà
L735Rà

728

728

AKDENSQRKSEVSKR 742

LKDENSQRKSEVSKL 742

Reverted Mutations
L728A/L735Rà

728

AKDENSQRKSEVSKL 742

Sequences represent the carboxyl terminal leucine zipper region of RHAMM from amino
acid 728 to 742 of the full-length protein. This region of RHAMM is proposed to
facilitate RHAMM-mitotic spindle interactions in cell culture. Initial mutations,
L735R/L742R and L728A/L735R/L742R, represent mutations that were generated by
site-directed mutagenesis to alter the leucine zipper function; mutated amino acid
residues are outlined in red. Reverted amino acids, obtained after selection for expression
of initial mutations, are indicated in blue
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Figure 3.1 RHAMMΔ163 Constructs
Wildtype and mutant RHAMMΔ163 cDNA were amplified by PCR and cloned into the
mammalian pHβ-APr1 expression vector in the Sal I and Bam HI sites. The vector is
driven by the β-actin promoter and contains a neomycin resistant gene for selection of
stable transfectants in 10T1/2 and RHAMM-/- MEFs
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RHAMM sequence containing the leucine zipper binds directly to tubulin in vitro
During mitotis, RHAMM localizes along the length of microtubules and this interaction
occurs via its carboxyl terminus. Within the C-terminal microtubule binding region is a
conserved leucine zipper that is thought to mediate RHAMM/mitotic spindle interactions.
Deletion of RHAMM fragments lacking the leucine zipper disrupts proper spindle
formation, thus owing to its essential role in maintaining mitotic spindle integrity (19, 73,
74)
Our lab has demonstrated that C-terminal RHAMM fragments bind to tubulin
heterodimers, in vitro, and this interaction can be disrupted by the addition of a
synthesized peptide containing the leucine zipper motif. To identify the mechanism by
which RHAMM associates with the mitotic spindle, we aimed to determine whether
RHAMM directly interacts with microtubules [tubulin heterodimers] via the leucine
zipper sequence. Direct interactions between commercially purified α/β-heterodimeric
tubulin and a C-terminal biotinylated wildtype RHAMM peptide (Table 3.2) containing
the leucine zipper were tested using an ELISA assay (Figure 2.1). Wildtype RHAMM
peptide showed specific binding to tubulin heterodimers in a concentration dependent
manner (Figure 3.2A); background binding was low, and these interactions were
abolished by competition with excess competitive RHAMM peptide (Figure 3.2B).
Furthermore, a scrambled peptide of the same amino acid residues showed positive, yet
nonspecific weak binding as this interaction could not be competed off with excess
competitive RHAMM peptide (Figure 3.2B). These results support the hypothesis that
RHAMM-tubulin interactions occur through the conserved C-terminal domain of
RHAMM and most importantly that these interactions occur directly.
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Table 3.2: RHAMM Peptide Sequences
Peptide

Sequence

Wildtype

Biotin-AEEA-QKIKHVVKLKDENSQLKSEVSKLRSQLVKRK-NH2

L735R

Biotin-AEEA-QKIKHVVKLKDENSQRKSEVSKLRSQLVKRK-NH2

Scrambled

Biotin-AEEA -LDRLKHVQKNKLSKSQKIVKSKVELRSQEVK-NH2

Competitive

Ac- QKIKHVVKLKDENSQLKSEVSKLRSQLVKRK-NH2

3.5 kDa RHAMM peptide sequence representing 31 amino acids of the C-terminal
domain of RHAMM (aa720-750), including the underlined leucine zipper proposed to
function in binding to the mitotic spindle. Three peptides were biotinylated at the Nterminus via a short PEG linker (AEEA) to allow for specific binding to streptavidin in
tubulin ELISA assay. The mutated amino acid residue in the leucine zipper of L735R is
highlighted in red. Scrambled peptide was generated by randomly rearranging the amino
acids of the wildtype peptide. Competitive peptide was used for a competitive ELISA
assay and was unlabeled but acetylated at the N-terminus end
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A)

3.0

Absorbance at 405 nm

2.5
2.0
1.5

Wildtype Peptide
L735R Peptide

1.0
0.5
0.0
5

10

20

40

Peptide Concentration (ug/ml)

B)

3.5

*

*

Absorbance at 405 nm

3
2.5
2

10 ug/ml Biotinylated Peptide
+100ug/ml Competitive Peptide
10 ug/ml Biotinylated Peptide

1.5
1
0.5
0
Wildtype

L735R

Scrambled
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Figure 3.2: Wildtype and mutant C-terminal RHAMM peptides directly bind to α-,
β-tubulin heterodimers in an ELISA assay
Direct and competitive tubulin ELISA assays were performed using purified α/β-tubulin
heterodimers and biotinylated C-terminal RHAMM peptides (aa 720-750) A) Direct
binding interactions of wildtype and mutant RHAMM peptides to tubulin were detected
in a concentration dependent manner B) Binding of biotinylated wildtype and mutant
RHAMM peptides to tubulin heterodimers was competed off with excess unlabeled
wildtype RHAMM peptide (aa 720-750). Scrambled peptide was not able to compete off,
confirming the specificity of the C-terminal RHAMM sequence to tubulin. Bars represent
mean ± S.E. of n=3 replicates; *p<0.05
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Mutation of the leucine zipper does not affect RHAMM binding to tubulin in vitro
The ELISA data confirmed the specific interaction of wildtype C-terminal RHAMM
peptide with tubulin heterodimers. To determine the role of the leucine zipper in this
interaction, a RHAMM peptide containing mutation L735R of the leucine zipper was
synthesized (Table 3.2) and its binding to tubulin was tested. A leucine zipper is a
common protein-protein interaction motif that contains heptad repeats of hydrophobic
leucine residues, which form amphipathic α helices used for parallel dimerization with
other proteins (129). Typically, the mutation of one leucine residue disrupts leucine
zipper function and thus the ELISA assay was only carried out for one mutant RHAMM
form. Mutating one leucine residue, L735R, in RHAMM’s leucine zipper, however, did
not disrupt binding to tubulin; under these conditions the L735R peptide retained an
ability to bind to tubulin in a concentration dependent manner (Figure 3.2A) and wildtype
unlabeled peptide was able to compete for its binding (Figure 3.2B). These results
demonstrate that although the C-terminal RHAMM sequence contained within this
peptide mediates direct binding to tubulin heterodimers, these interactions were not
through the leucine zipper dimerization motif, as disruption of its function did not abolish
binding to tubulin.
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3.2 Objective 2: Assessing the role of RHAMMΔ163 in mitotic
spindle functions and tumorigenesis

Overexpression of wildtype and mutant RHAMMΔ163 in fibroblasts does not
promote cell proliferation to similar extents
Our in vitro data confirmed that RHAMM binds directly to tubulin via its carboxy
terminal domain and that the leucine zipper motif does not mediate this binding. To
determine if this interaction was retained in cell culture and if leucine zipper mutations
abolished RHAMM/mitotic spindle interactions, GFP-tagged RHAMMΔ163, both
wildtype and mutant forms, were expressed in 10T1/2 cell lines. Interestingly, expression
of GFP fusion proteins under a strong CMV promoter resulted in cell death; hence we
were unable to obtain stable transfectants. GFP fusion proteins were thus expressed under
the β-actin promoter to reduce deleteriously high RHAMM expression. Stable
transfectants were selected for with G418, however, under selection pressure few G418resistant colonies showed any detectable green fluorescence and expression rapidly
declined. As an alternate approach, transient expression of GFP- RHAMMΔ163 was used,
however, this resulted in too low of an expression to be useful. Thus assessing the direct
effects of mutant RHAMMΔ163 expression on mitotic spindle interactions in culture
proved to be difficult using this approach.
As an alternative method, cellular events that are relevant to mitotic spindle formation
were used as surrogate markers to indirectly assess if RHAMM/mitotic spindle
interactions were perturbed. Based on previous publications, we assumed that leucine
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zipper mutations would abolish RHAMM/mitotic spindle interactions and that cellular
events including cell proliferation, cell cycle progression, and apoptosis would be altered.
Overexpression of RHAMM mRNA and protein levels was first confirmed in established
stably transfected 10T1/2 cell lines by qPCR and western blot analysis, respectively.
10T1/2 parental MEFs express low levels of endogenous RHAMM forms, including
RHAMMΔ163 and full-length RHAMM (RHAMMFL). RHAMM mRNA expression in
10T1/2- RHAMMΔ163, 10T1/2- RHAMMΔ163-L735R, and 10T1/2- RHAMMΔ163L728A/L735R cells were significantly higher than parental 10T1/2 fibroblasts, with a
~2.6-2.8 fold increase in expression (Figure 3.3A, B). Western blot analysis displayed a
similar expression pattern with parental 10T1/2 fibroblasts displaying low levels of
endogenous RHAMMΔ163 compared to wildtype and mutant 10T1/2- RHAMMΔ163
expressing cells, which displayed higher levels of ectopic RHAMMΔ163. Levels of
endogenous RHAMMFL served as the loading control (Figure 3.4).
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Figure 3.3: mRNA expression levels of RHAMM in 10T1/2 MEFs
10T1/2 MEFs were transfected with RHAMMΔ163, RHAMMΔ163-L735A, or
RHAMMΔ163-L728A/L735R, and a mixed pool of transfectants were selected for using
G418. cDNA from parental 10T1/2 MEFs and 10T1/2 MEFs stably expressing wildtype
or mutant RHAMMΔ163 were analyzed by qRT-PCR using RHAMM specific primers.
Relative expression levels of the RHAMM gene were determined using the standard
curve method with expression normalized to 28S mRNA. A) 10T1/2 MEFs expressing
RHAMMΔ163 and L728A/L735R showed a 2.8 and 2.6 fold increase in RHAMM
expression, respectively, compared to control 10T1/2 MEFs which express low levels of
endogenous RHAMM B) 10T1/2 MEFs expressing L735R showed a 2.8 fold increase in
RHAMM expression compared to control 10T1/2 MEFs. Data represents the mean of
n=3 replicates ±S.E; *p<0.05
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Figure 3.4: RHAMMΔ163 protein levels in 10T1/2 fibroblasts
10T1/2 MEFs were transfected with w RHAMMΔ163, RHAMMΔ163-L735A, or
RHAMMΔ163-L728A/L735R, and a mixed pool of transfectants were selected for using
G418. Whole cell lysates were prepared and analyzed by western blotting. RHAMMΔ163
protein expression was determined by hybridization with a monoclonal RHAMM
antibody recognizing sequences in the N-terminus. As expected, 10T/12 parental cells
express low levels of endogenous RHAMMΔ163 compared to ectopic overexpression of
RHAMMΔ163 in established stable 10T1/2 cell lines. Expression of endogenous fulllength RHAMM (RHAMMFL) was used as a loading control as this form is detected
using the same RHAMM antibody
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The first aim was to determine whether ectopic overexpression of RHAMMΔ163 promoted
cell proliferation in 10T1/2 MEFs by using the innate reducing ability of cells to convert
exogenously added alamarBlue reagent, resazurin, into a measurable fluorescent product,
resorufin. Results unexpectedly showed that the proliferation of 10T1/2-RHAMMΔ163
fibroblasts was significantly reduced over the duration of 96 hours compared to 10T1/2
parental MEFs. The greatest difference in proliferation was seen at 48 and 72 hours post
cell plating (Figure 3.5A).
RHAMM-/- fibroblasts provide a cleaner system to study the effects of RHAMMΔ163 on
cell proliferation since they lack endogenous RHAMM. Similar to 10T1/2 MEFs, stable
overexpression of RHAMMΔ163 in RHAMM-/- cells showed a decrease in cell
proliferation (Figure 3.6A).
Overexpression of RHAMMΔ163-L735R or RHAMMΔ163-L728A/L735R in 10T1/2 MEFs
similarly decreased proliferation when compared to parental fibroblasts (Figure 3.5B).
However, they did not alter proliferation when compared to RHAMMΔ163; L735R growth
was not significantly different from RHAMMΔ163, while L728A/L735R expressing
fibroblasts showed a subtle, yet significant, increase in proliferation at 24, 48, and 72
hours, though the significance of these results were variable between experiments (Figure
3.5C). Furthermore, expression of L735R mutant in RHAMM-/- (KO) cells showed
significant, yet minor affects on cell proliferation compared to RHAMMΔ163 expressing
cells (Figure 3.6B).
Collectively, these results demonstrate that overexpression of RHAMMΔ163 inhibits rather
than stimulates proliferation of 10T1/2 and RHAMM-/- fibroblasts and disrupting the
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leucine zipper does not further affect this function. However, expression of
RHAMMΔ163-L728A/L735R significantly increased proliferation compared to
RHAMMΔ163 suggesting a plausible role for specific leucine residues, but not a leucine
zipper function in RHAMM effects on proliferation.

68

A)

Fluorescence Units

750000
600000
450000
300000

10T1/2
RHAMMΔ163

*

150000

*

0
0

24

48

72

96

120

Time (hours)

B)

Fluorescence Units

750000
600000
450000
300000

10T1/2
L735R
L728A/L735R

*

150000

*

0
0

24

48

72

96

120

Time (hours)

C)

Fluorescence Units

500000
400000
300000

*

200000

RHAMMΔ163

*

100000

L735R

*

L728A/L735R

0
0

24

48

72

Time (hours)

96

120

69

Figure 3.5: Overexpression of wildtype and mutant RHAMMΔ163 in 10T1/2
fibroblasts does not promote cell proliferation
Cell proliferation of parental 10T1/2 MEFs and 10T1/2 fibroblasts expressing
RHAMMΔ163, RHAMMΔ163-L735R, and RHAMMΔ163-L728A/L735R was assessed by
alamarBlue reagent. A) Overexpression of RHAMMΔ163 in 10T1/2 MEFs decreases cell
proliferation over the course of 96 hours. B) Expression of RHAMMΔ163-L735R or
RHAMMΔ163-L728A/L735R, in 10T1/2 MEFs similarly decreases cell proliferation. C)
Overexpression of RHAMMΔ163-L735R has subtle affects on cell proliferation compared
to RHAMMΔ163. The results represent mean fluorescence units ±S.E of n=9 replicates. *
p<0.05
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Figure 3.6: Expressing RHAMMΔ163 –L735R in RHAMM-/- fibroblasts does not
drastically alter cell proliferation
Cell proliferation of KO- RHAMMΔ163 and KO- RHAMMΔ163–L735R cells were assessed
using alamarBlue reagent. A) Overexpression of RHAMMΔ163 in RHAMM-/- fibroblasts
results in a decrease in cell proliferation over 96 hours. B) Overexpression of
RHAMMΔ163-L735R has subtle affects on cell proliferation. The results represent mean
fluorescence units of n=9 replicates per cell per cell line ±SE *p<0.05
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Overexpression of wildtype or mutant RHAMMΔ163 does not alter cell cycle
progression when expressed in 10T1/2 MEFs
RHAMM expression is tightly regulated during the cell cycle and levels of RHAMM
peak at G2/M. Mutating the mitotic spindle-binding region of RHAMM would thus be
expected to impact cell cycle progression. Previous studies have shown that
overexpression of RHAMM isoforms in certain cell lines results in a mitotic arrest at
G2/M (19). We therefore first determined if overexpression of RHAMMΔ163, in 10T1/2
mouse embryonic fibroblasts similarly blocked cell cycle progression.
Cell cycle profiles of asynchronous 10T1/2- RHAMMΔ163 MEFs, as demonstrated by
DNA content using PI staining and subsequent flow cytometry, revealed similar profiles
with distinct G1, S, and G2/M peaks as parental 10T1/2 MEFs at 24 hours post culturing
(Figure 3.7A,B). The percentage of cells in each stage of the cell cycle did not differ
significantly between the two populations (Figure 3.7C). Results suggest that a 2.8 fold
increase in RHAMM mRNA expression was not sufficient to arrest the cells in mitosis.
Likewise, expression of RHAMMΔ163-L735R or RHAMMΔ163-L728A/L735R did not
significantly alter 10T1/2 cell cycle progression when compared to either parental cells or
RHAMMΔ163 expressing fibroblasts. The percentages of cells in the different stages of the
cell cycle—G1, S and G2/M—were not significantly different between the different
populations (Figure 3.7C), suggesting leucine zipper mutations do not impact cell cycle
progression.
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Figure 3.7: Overexpression of wildtype or mutant RHAMMΔ163 in asynchronous
10T1/2 fibroblasts does not alter cell cycle progression
DNA content of asynchronous 10T1/2 parental and 10T1/2- RHAMMΔ163 cells, both
wildtype and mutant (L735R or L728A/L735R), was stained with propidium iodide and
analyzed by flow cytometry. Representative histograms of DNA content during the cell
cycle of A) 10T1/2 parental cells and B) 10T/12- RHAMMΔ163 transfected cells. Grey
outline of each graph represents the Watson-Pragmatic model of cell cycle analysis C)
Cell cycle distribution of 10T1/2 parental and 10T1/2 cells expressing RHAMMΔ163,
RHAMMΔ163-L735R, and RHAMMΔ163-L728A/L735R expressed as a percent obtained
via the Watson Pragmatic model. Overexpression of RHAMMΔ163 –L735R or
RHAMMΔ163 –L735R/L728A/L735R had no effect on cell cycle progression. Each
column represents the mean of n=4 independent experiments ± S.E; n.s indicates no
statistical significance between 10T1/2 parental cells or 10T1/2- RHAMMΔ163 cells in the
same phases of the cell cycle, p>0.05
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Expression of mutant RHAMMΔ163 forms in 10T1/2 MEFs does not affect cell
apoptosis
Since RHAMM is known to play a role in mitotic spindle integrity, we speculated that
mutations in the putative mitotic spindle-binding region would contribute to aberrations
during spindle assembly. Consequently, an accumulation of defects in mitotic spindle
assembly has the potential to trigger the apoptotic machinery. To assess if mutations
made in the leucine zipper of RHAMM would alter the number of apoptotic cells, levels
of apoptosis of 10T1/2 MEFs stably expressing RHAMMΔ163, L735R or L28A/L735R
were assessed. The presence of cytoplasmic histone-associated DNA fragments that were
present after cell death was quantified from cell lysates of both wildtype and mutant
10T1/2-RHAMMΔ163 cells using ELISA. Expression of L735R or L728A/L735R
RHAMMΔ163 did not induce changes in apoptosis when compared to RHAMMΔ163
expressing MEFs (Figure 3.8). This suggests that mutations in the leucine zipper
sequence of RHAMM do not have an effect on cell death.
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Figure 3.8: Expression of mutant RHAMMΔ163 forms in 10T1/2 MEFs does not
affect apoptosis
Lysates of 10T1/2-RHAMMΔ163, 10T1/2- RHAMMΔ163 -L735R and 10T1/2-RHAMMΔ163
-L728A/L735R fibroblasts were analyzed 24 hours post seeding to determine levels of
apoptosis. Cell death was assessed using an ELISA assay detecting mono- and
oligonucleosomes using anti-histone and anti-DNA antibodies. Each column represents
the mean absorbance of n=4 replicates ± S.E; n.s indicates no statistical significance from
RHAMMΔ163, p>0.05

77

Mutant 10T1/2- RHAMMΔ163 expressing fibroblasts retain the ability to form tumor
xenografts in immune compromised mice
Our lab has shown that overexpression of RHAMMΔ163 in 10T1/2 mouse embryonic
fibroblasts results in cell transformation as shown by tumor formation in immune
compromised mice (95) and this ability has been linked to genomic instability generated
by aberrant mitosis in multiple myeloma (81). Cell transformation was used as a
surrogate marker to assess a change in tumor formation if RHAMM/mitotic spindle
interactions were altered. To determine whether mutant RHAMMΔ163 retains oncogenic
effects and in turn to assess if a mutated leucine zipper affects the transforming potential,
10T1/2 MEFs expressing RHAMMΔ163, RHAMMΔ163 -L735R or RHAMMΔ163 L728A/L735R were subcutaneously injected in the flank of NSG mice and tumor growth
was monitored. Both 10T1/2- RHAMMΔ163-L735R and 10T1/2- RHAMMΔ163L728A/L735R retain their ability to form tumor xenografts (Table 3.3). Tumors were
excised and their wet weights determined (see Appendix A). The differences in tumor
weights, however, could not be compared as tumor-forming capabilities varied between
experiments. These results suggest that disruption of the leucine zipper does not have
strong effects on tumorigenesis as mutant RHAMMΔ163 forms still formed tumor
xenografts in immune compromised mice.
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Table 3.3: Summary of transforming abilities of 10T1/2 fibroblasts
Cell Type

Transforming?

10T parental MEFs

NO

10T Empty Vector

NO

10T RHAMMΔ163 MEFs

YES

10T RHAMMΔ163 –L735R MEFs

YES

10T RHAMMΔ163 –L728A/L735R MEFs

YES

10T1/2 parental and RHAMMΔ163 expressing (wildtype or mutant) fibroblasts were
subcutaneously injected in the flank of NSG mice and tumor growth was monitored over
6 weeks. L735R and L728A/L735R fibroblasts retain the ability to transform cells and
form tumors in mice. Ability to transform is based on tumor formation seen in triplicate
mice per cell line injected. 10T1/2 parental and 10T1/2 empty vector cells serve as the
negative controls, while 10T1/2 RHAMMΔ163 served as the positive control
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3.3 Objective 3: Assessing the role of RHAMM Δ163 in
directed cell migration

Mutant RHAMMΔ163 expression in RHAMM-/- MEFs causes defects in cell
migration due to loss of directionality
Tight control of centrosomal function is essential not only for proper cell division, but
also for directed cell migration. Defects in the function, structure, number, or position of
centrosomes can contribute to aberrant cell migration and division due to loss of polarity.
The carboxy terminal leucine zipper of RHAMM is known to function in binding to and
modulating the position of centrosomes (19, 84). RHAMM also plays an essential role
during cell migration and its genetic deletion results in an inability of cells to resurface
scratch wounds with a concomitant decrease in motility rate, which can be rescued by
RHAMM expression. To determine the effects of L735R-RHAMMΔ163 expression on
directed cell migration and if these cells were able to rescue the motility defects in
RHAMM-/- MEFs, we conducted scratch wound assays on RHAMM-/- cells stably
expressing RHAMMΔ163 or RHAMMΔ163-L735R. This assay assesses the ability of cells
to move into a cell-free area created by scraping the center of a confluent monolayer of
cells. Time-lapse analysis of the scratch-wounds revealed significantly fewer mutant
RHAMMΔ163-L735R cells present in the scratches compared to RHAMMΔ163 cells
(Figure 3.9A-C). The differences seen in cell migration were not due to differences in
cell growth, as expression of RHAMMΔ163-L735R in RHAMM-/- cells did not inhibit cell
proliferation (Figure 3.6B). These results suggest that a mutation in the leucine zipper of
RHAMMΔ163 (L735R) impacts the ability to recover scratch wounds.
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Figure 3.9: RHAMMΔ163 –L735R expression in RHAMM-/- MEFs causes defects in
cell migration
Confluent monolayers of RHAMM-/- (KO) MEFs stably expressing RHAMMΔ163or
RHAMMΔ163-L735R were cultured overnight and subsequently scratched using a sterile
pipette tip. Wound closure was assessed by time-lapse microscopy at the indicated time
points at 4x magnification. Images from a representative experiment of A) KORHAMMΔ163 and B) KO-RHAMMΔ163–L735R at different time points are shown. C)
Fewer number of KO-RHAMMΔ163–L735R cells migrated into the scratch wound. Data
represents the mean of three randomized areas of the scratched wound with error bars
representing standard error. * p<0.05
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Furthermore, the defects in migration could account for a reduced rate of motility or
altered directional movement. To identify if RHAMMΔ163-L735R fails to promote speed
or direction of movement, the motility of individual cells from the scratch wound assays
were tracked using vector analysis. Results show that RHAMMΔ163-cells migrated further
distances away from the cell origin compared to RHAMMΔ163-L735R expressing cells
(Figure 3.10A-C). Whereas RHAMMΔ163 cells migrated into the wound, the
directionality was disturbed in RHAMMΔ163-L735R cells, which traveled back into the
monolayer resulting in a decrease in distance migrated from the cell origin (Figure
3.10C). The L735R mutant did not affect overall distance travelled by the cells and
therefore did not have a significant impact on rate of motility (Figure 3.10D). Note that
RHAMM-/- fibroblasts are directionally and speed impaired and these defects are rescued
by RHAMMΔ163 expression. Thus, mutating the leucine zipper of RHAMMΔ163 rescued
speed, but did not rescue the directionality defects of RHAMM-/- fibroblasts.
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Figure 3.10: KO-RHAMMΔ163-L735R fibroblasts migrate shorter distances from the
cell origin
Confluent monolayers of RHAMM-/- (KO) MEFs stably expressing RHAMMΔ163or
RHAMMΔ163-L735R were cultured overnight and subsequently scratched using a sterile
pipette tip. Wound closure was assessed by time-lapse microscopy overnight at 4x
magnification. The motility of individual cells was tracked using NIS Elements imaging
software. Representative images of the path of individual A) KO-RHAMMΔ163 and B)
KO-RHAMMΔ163-L735R- fibroblasts as they migrate into the scratch wounds C)
Average distance of cells at the wound edge as they travel from cell origin D) Average
path length fibroblasts traveled from wound edge Mean ±SE, n=10, *p<0.05
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Percentage of KO-RHAMMΔ163-L735R cells with n>1 centrosome was greater than
KO- RHAMMΔ163 –rescued cells
Our results suggested that there was a migration defect when expressing RHAMMΔ163
mutated in the leucine zipper region. Since this region is known to bind to centrosomes
and regulates their structure/function, we next determined if centrosome number or
location within the RHAMMΔ163 –L735R expressing cells was altered.
KO, KO-RHAMMΔ163, and KO-RHAMMΔ163-L735R expressing cells were seeded on
coverslips and confluent monolayers were scratched and allowed to recover before
staining the cells with a centrosome marker, pericentrin, and DAPI to stain the nucleus.
Cells at the wound edge were imaged (Figure 3.11A-D) and the number and location of
centrosomes were quantified. The percentage of non-dividing cells with more than one
centrosome was greatest in KO- RHAMMΔ163-L735R cells (Figure 3.11E). Additionally,
the location of the centrosome with respect to the cell nucleus was altered in KORHAMMΔ163-L735R cells in that there were a greater percentage of cells with
centrosomes behind the nucleus; however, it was not significantly different from KORHAMMΔ163 or KO cells (Figure 3.11F). These results suggest that RHAMM leucine
zipper may play a functional role in regulating centrosome number, but not in centrosome
placement/position.
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Figure 3.11: The percentage of cells with n>1 centrosome is greatest in KORHAMMΔ163-L735R
KO, KO- RHAMMΔ163, and KO- RHAMMΔ163-L735R expressing fibroblasts were grown
to confluency overnight and subsequently scratched using a sterile pipette tip. Cells were
fixed and stained with the centrosome marker, pericentrin, and DAPI to visualize the
nucleus. Cells at the wound edge were imaged at 20x magnification and analyzed.
Representative immunofluorescent images of A) mitotic figures that were not included in
the analysis, B) KO- RHAMMΔ163-L735R, C) KO- RHAMMΔ163 and D) KO parental
cells, where green represents pericentrin staining, blue represents DAPI staining, and the
dashed line represents the wound edge E) The percentage of cells with n>1 centrosome
was greatest in KO- RHAMMΔ163-L735R cells compared to KO or KO- RHAMMΔ163
cells. F) The orientation of the centrosome with respect to the cell nucleus was not
altered in KO- RHAMM

Δ163

–L735R expressing cells compared to either KO-

RHAMMΔ163 or parental KO cells. Data represents the percentage of the average number
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of counted cells: 517 KO, 488 KO- RHAMMΔ163, and 483 KO- RHAMMΔ163-L735R;
*p<0.05, n.s indicates no statistical significance compared to KO or KO- RHAMMΔ163
where p>0.05.
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Chapter 4

4

General Discussion

4.1 Role of RHAMM in mitotic functions

Several reports have established a role for RHAMM in binding to and regulating mitotic
spindle integrity (19, 20, 73). During the mitotic phase of the cell cycle, RHAMM
localizes to the mitotic spindle along the length of microtubules and is particularly
concentrated at the spindle poles (20, 69, 74). Genetic deletion or inhibition of
endogenous RHAMM forms results in abnormal mitotic figures with multi-polar mitotic
spindles (19, 20, 74). Silencing of RHAMM also impacts the kinetics of mitosis and
results in a delay in spindle assembly and in mitotic completion (100), suggesting a role
for RHAMM in mediating microtubule assembly. Further experiments reveal that
RHAMM also impacts positioning of the mitotic spindle and thus helps establish an
oriented bipolar spindle (93, 100).
Consistent with RHAMM’s role in regulating mitotic spindle functions, the RHAMM
gene is cell cycle regulated and its expression increases during G2/M, a stage in the cell
cycle where a cell prepares for and subsequently undergoes mitosis (4, 111). Blocking
cell surface or knockdown of intracellular RHAMM forms results in a slower progression
of cells through G2/M and a fewer percentage of cells at G2/M, respectively (91, 109).
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Previous literature utilizing deletion constructs of carboxyl terminal RHAMM fragments
have narrowed down the last 100 amino acid residues containing a leucine zipper motif to
be essential in localizing RHAMM to mitotic spindles (19). Mutational analysis of the
leucine residues in the leucine zipper to arginines further revealed that this particular
region serves a functional role in proper aster spindle formation in Xenopus egg extracts
and was thus required for mitotic spindle integrity (20, 73, 100). The latter study made
use of a C-terminal RHAMM peptide corresponding to the leucine zipper that when
present in excess disrupts aster spindle formation. When mutated in the leucine zipper
motif, however, the peptide does not display defects in spindle assembly. The effects of
this regulation were dependent on the presence of BRCA1/BARD1 complex, whose role
was predicted to safeguard the formation of a bipolar mitotic spindle (73, 78). The
authors of the study concluded that the leucine zipper motif is therefore functionally
important in regulating spindle integrity. Results from this study and other works
showing that deletion of RHAMM has a similar effect on spindle integrity indicates that
RHAMM levels must be tightly regulated throughout the cell cycle, since its deletion or
forced high expression results in abnormal mitosis
The mechanism by which RHAMM mediates spindle pole assembly and regulation is
complex, involves numerous factors, and not fully understood. The literature, however,
highlights an important role for the leucine zipper motif within RHAMM’s carboxyl
terminus in mediating direct and indirect effects via its binding partners.
Work in our lab has demonstrated a putative mechanism by which the carboxyl terminal
of RHAMM directly regulates the mitotic spindle and this is through its direct
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interactions with tubulin heterodimers [microtubules] as this interaction can be competed
off using a synthesized peptide containing the leucine zipper sequence (20).
Additionally, several reports have established that RHAMM/centrosome interactions,
also mediated through the leucine zipper, are essential for mitotic spindle integrity in a
variety of cell types (19, 84). Mutational analysis of the centrosomal binding region of
RHAMM not only results in less RHAMM localized around centrosomes, but also
spindle pole defects characterized by tetrapolar mitotic figures (84).
Furthermore, recent work has identified a role of RHAMM leucine zipper to be essential,
although not sufficient, in mediating interactions with the spindle assembly protein
factor, TPX2. This study also proposed that the major effect of RHAMM on mitotic
spindle function was mediated by TPX2, which binds to the leucine residues of the
leucine zipper (73, 100). RHAMM/TPX2 interactions are seen in several cell types and
are important for proper microtubule and spindle assembly (100). Mutation of the three
conserved leucine amino acids of the leucine zipper sequence in RHAMM to arginines
disrupted TPX2 localization at the spindle poles and consequently proper activation of
AURKA kinase activity(100). AURKA is an important regulator of the cell cycle and is
essential for progression through mitosis (17).
Collectively, previous data suggests that RHAMM mediates binding to microtubule
structures, centrosomes, and the spindle assembly protein factor TPX2 through its
carboxyl terminal leucine zipper sequence and these interactions play a role in the
regulation of the mitotic spindle. Although these studies established a critical role for
leucine zipper sequence, they did not assess a role for its dimerization function; the
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consequences of mutating only one leucine residue, which would have compromised the
dimerization motif of a leucine zipper, was not reported in these studies.
With this in mind, this study first aimed to assess if RHAMM/microtubule interactions
were mediated through a leucine zipper function and to ascertain if an intact leucine
zipper was required for mitotic spindle integrity. The experimental approach that was
taken was to disrupt the leucine zipper by site mutating single leucine residues. In doing
so, we could assess if the leucine zipper function of dimerization was responsible for
interactions with microtubules and the mitotic spindle.
RHAMM interactions with microtubules [tubulin heterodimers], in vitro, were first
assessed using synthesized RHAMM peptides containing the leucine zipper, both
mutated and wildtype sequences. The consequences of a mutated leucine zipper on
mitotic spindle assembly in culture were not directly assessed due to the difficulty in
expressing GFP-tagged RHAMMΔ163. The effects of the leucine zipper mutations on
RHAMM/mitotic spindle integrity were therefore examined indirectly using cell
proliferation, cell cycle progression, and apoptosis as surrogate markers. Based on
previous literature, it was predicted that RHAMM’s interactions with microtubules and
the mitotic spindle would be disrupted and that alterations in key cellular events would be
evident.
Studies confirmed that RHAMM/tubulin interactions occur directly through RHAMM’s
carboxyl terminus, but most importantly showed that this binding was not mediated by
the leucine zipper motif. Under the conditions of this study, the ability of the L735R
mutant to bind to tubulin was not compromised since it bound in similar amounts as
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wildtype and since wildtype RHAMM peptide retained an ability to compete with L735R
for binding to tubulin. RHAMM/tubulin interactions therefore do not require
dimerization through a leucine zipper; however, the C-terminal RHAMM peptide used in
this assay contains a site for microtubule binding.
Furthermore, studies showed that disruption of the leucine zipper motif did not appear to
have significant effects on mitotic spindle functions as assessed using the surrogate
markers of cell proliferation, cell cycle progression and apoptosis.
A minor inhibition of proliferation was seen in RHAMMΔ163 –transfected cells, however,
the differences in proliferation between RHAMMΔ163-L735R, RHAMMΔ163L728A/L735R, and RHAMMΔ163 –expressing fibroblasts were very subtle in both 10T1/2
and RHAMM-/- cell backgrounds. There were, however, slight differences observed in
cell growth between L735R- and L728A/L735R-RHAMMΔ163 forms. These disparities,
combined with our studies showing the apparent reversion of the third leucine in the
leucine zipper region under selection pressure, predict a functional role of individual
leucine residues as opposed to a leucine zipper function during cellular processes. The
leucine zipper domain partially overlaps with the ERK docking site and the HA binding
region and thus mutation of specific residues could impact on these functions, as
RHAMM dependent ERK activation and RHAMM-HA interactions are known to
mediate cell proliferation in numerous cell backgrounds (67, 109, 130, 131).
In addition, RHAMMΔ163 did not alter 10T1/2 cell cycle progression compared to
parental cells and disrupting the leucine zipper via expression of L735R or L728A/L735R
did not modify the percentage of cells in each stage of the cell cycle. Given that
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RHAMM is tightly regulated throughout the cell cycle and peaks at G2/M, if mitotic
spindle assembly were compromised due to disrupted RHAMM/mitotic spindle
interactions, a block in the mitotic phase of the cell cycle would be evident. Cells would
be expected to arrest at G2/M, however this did not seem likely given our data.
Furthermore, while we did not look at the cell cycle profile of synchronized cells, it is
possible that these mutations impact the rate of cell cycle progression in a minor way,
which has been shown to be RHAMM regulated (100).
Data presented here further suggests that mutations in the leucine zipper motif do not
impact apoptosis since levels of cell death did not differ between wildtype and mutant
RHAMMΔ163-transfected 10T1/2 cells. Defects in mitotic spindle assembly or regulation
have the potential to trigger the apoptotic machinery (84), but this did not appear likely in
these studies.
The conflicting data in the literature pertaining to RHAMM’s role during cell
proliferation and cell cycle progression could partially be attributed to the levels of
RHAMM protein expression and to the numerous RHAMM isoforms present in cell lines
and in human cancers. The levels of spindle assembly protein factors must be finely
tuned since abundance or inhibition can abrogate their function and regulation of the
mitotic spindle (132). Certainly, RHAMM protein levels could contribute to the
differences between the work presented here and previous studies showing that cells
arrest at G2/M when RHAMM was ectopically overexpressed. For example, this study
showed that 2.8-fold overexpression of RHAMM does not have an impact on the
percentage of cells in different stages of the cell cycle, whereas other studies show that a
5-fold overexpression of RHAMM arrests cells in G2/M (19).
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Although the mechanism underlying the expression pattern or presence of the different
RHAMM isoforms is not well established, studies predict that specific forms are
generated during particular responses, localize to distinctive subcellular compartments
and the effects they exert are often context-dependent and cell-type specific (69, 92, 94).
Additionally, previous works often fail to indicate which RHAMM isoform is being
studied/investigated, thus making it difficult to establish the specific functions of each
RHAMM form and to elucidate the effects they have during particular cell processes.
The discrepancy in cell proliferation seen in this study and previous work showing
RHAMM either promotes or has no effect on cell proliferation may largely be due to
differences in cell backgrounds. Studies showing no effect on cell proliferation when
RHAMM expression is downregulated do, however, show that cell migration and
invasion is inhibited in invasive breast cancer cell lines (133).
The proliferation data on fibroblasts in this study, however, are consistent with previous
literature suggesting that RHAMM overexpression does not promote cell growth and may
even have an inhibitory effect on proliferation (117). This effect is quite surprising and
unexpected given that overexpression of wildtype and mutant RHAMMΔ163 forms
transformed 10T1/2 fibroblast cell lines and formed tumors when cells were injected in
NOG immune compromised mice. While this was not the major focus of this study, these
results suggest that the effect of RHAMMΔ163 isoform on 10T1/2 cell transformation is
therefore unrelated mechanistically to cell proliferation. To our knowledge, this is the
first study relating the tumorigenic properties of RHAMMΔ163 isoform in 10T1/2 MEFs
to cell proliferation.
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4.2 Functions of RHAMM in directed cell migration

RHAMM also plays an essential role during cell migration. Given that RHAMM binds to
centrosomes via the leucine zipper motif and that an intact centrosome is required for
proper cell migration (19, 42), the second aim of this thesis was to determine if RHAMM
mutated in the leucine zipper impacts directed cell motility. An underlying defect seen in
RHAMM-/- fibroblasts is their inability to resurface scratch wounds due to their decreased
rate of motility compared to wildtype or RHAMM rescued counterparts (64). The defects
seen in migration are known to be due to aberrant activation of ERK1,2, but also were
hypothesized to be a result of defects in centrosome function (64). Centrosomes are the
main constituents of the MTOC and play an integral role during directed cell migration
by polarizing the cell and positioning the MTOC in the direction of migration relative to
the cell nucleus (124). RHAMM has been shown to not only regulate the position and
function of centrosomes, but also cell polarization during migration (124).
RHAMMΔ163-L735R-transfected RHAMM-/- fibroblasts showed a defect in cell migration
that was characterized by fewer migrating cells into the scratch wounds and that was not
attributed to a difference in cell proliferation. The alteration in migration could account
for a reduced cell motility rate or aberrant directional cell migration. Tracking the
motility of individual cells at the wound edge established that L735R- RHAMMΔ163
transfected fibroblasts traveled shorter distances from the cell origin, with decreased, yet
comparable motility rates as RHAMMΔ163 expressing cells. Whereas RHAMMΔ163 –
rescued cells moved into the scratch wounds, a portion of L735R- RHAMMΔ163
expressing cells were directionally impaired as these cells traveled back into the
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monolayer before moving into the scratch wound space. Interestingly, expression of
L735R mutant resulted in the appearance of a small subset of cells with polycentrosomes
during interphase. While a number of RHAMMΔ163 expressing cells also had more than
one centrosome, the percentages were not different from RHAMM-/- parental fibroblasts.
Previous studies had established a role for RHAMM in regulating centrosome volume in
multiple myeloma plasma cells, but not centrosome number (81). Data from this study
was based on experiments showing that centrosome number was not altered when
RHAMM levels were overexpressed (81). This is consistent with work presented here in
that overexpression of RHAMMΔ163 did not show an impact on centrosome number in
RHAMM-/- cells, however, when mutating the centrosome binding region (i.e. leucine
zipper) we saw an increase in the number of centrosomes per cell, suggesting a functional
role of the leucine zipper in centrosome regulation, perhaps affecting centriolar
replication. RHAMM is a known constituent of the pericentriolar material surrounding
centrioles in the MTOC and regulation of PCM proteins is essential during centrosome
duplication and separation; slight differences in the levels and function of PCM
components have been shown to impact cell polarity (134, 135). Whether RHAMM plays
a role in centrosome replication remains to be determined, but results here hypothesize
that it is likely contributing and thus affecting cell directionality.
Furthermore, while the majority of L735R- RHAMMΔ163 fibroblasts were frontpolarized, there was a trend for a greater number of cells that were rear-polarized (i.e.
centrosome behind the nucleus), however, the percentages were not drastically different
from RHAMMΔ163 or parental RHAMM-/- cells. This trend is consistent with RHAMM’s
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role in regulating the position of centrosomes (84) and also suggests that this regulation
partially depends on an intact leucine zipper motif.
While the work presented here showed that expression of RHAMMΔ163-L735R in
RHAMM-/- increases the number of polycentrosome cells, it did not establish whether
this defect is associated to the directional defects seen in cell migration. Given that
centrosomes help polarize and direct the cell during migration, we predict that the
centrosome defect in L735R- RHAMMΔ163 cells may account for a defect in directional
migration. Collectively, these results and hypothesis are supported by data showing that
disrupted centrosomes in an epithelial cell line migrate at slower rates, though not
significantly different from control cells, and in a disoriented direction away from the
scratch wound, due to loss of polarity (42).
It is well established that polycentrosomic cells contribute to defects in spindle pole
assembly during mitosis (84, 135). However, the effects of polycentrosomes during
interphase on non-mitotic functions are not well known. Recent work has identified that
supernumery centrosomes impact directed cell migration of endothelial cells (135).
Excess centrosomes, even one extra, resulted in altered directed cell migration with
reduced distance traveled from cell origin into a scratch wound. Centrosome positioning
was perturbed and centrosomes were more scattered; these defects could be partially
rescued by ablating excess centrosomes and were shown to be independent of mitotic
functions(135).
This seemingly contradictory data suggests that polycentrome cells would result in multipole mitotic spindles, though it doesn’t appear likely from our data. It is important to
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note, however, that mitotic spindle and migration studies were investigated in 10T1/2 and
RHAMM-/- fibroblasts, respectively. The distinctive cell backgrounds could contribute to
the difference in results but warrants further investigation.
An alternate interpretation for our results is that the defect in RHAMM’s regulation of
centrosomes via its leucine zipper motif could have subtle affects on rate of cell cycle
progression. Centrosomes begin replication during the S phase of the cell cycle, alongside
DNA replication, and begin to separate during prophase of mitosis to initiate a bipolar
mitotic spindle. A minor defect in the replication/separation of centrosomes could
account for the presence of numerous cells with more than one centrosome. Future work
will aim to investigate the contributing factors to migration defects and to elucidate
RHAMM’s regulation of centrosome replication during mitosis and migration.
Taken together, the data here suggests that the leucine zipper motif is critical for directed
cell migration in fibroblasts. Despite mutations in the leucine zipper, expression of
L735R- RHAMMΔ163 was able to rescue the rate of motility defect, though not
directionality of RHAMM-/- fibroblasts. Further studies are needed to reveal a mechanism
for RHAMM leucine zipper and centrosome interaction in directed cell migration and
polarity. Previous work in our lab has established a role of RHAMM in random and
directed motility that is dependent on RHAMM regulated ERK activation and subcellular
localization (64). Future work will examine the impact of and the levels of ERK
activation in mutant RHAMMΔ163-expressing fibroblasts.
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4.3 Summary and future studies

Our work suggests that the mechanism by which RHAMM regulates mitotic spindle
integrity is very complex and involves multiple regulatory factors. To our knowledge,
this is the first RHAMM study directly assessing a role for its leucine zipper dimerization
motif on mitotic spindle functions and migration. While previous literature has no doubt
established a vital role for leucine zipper sequence of RHAMM in maintaining mitotic
spindle integrity, results here suggest that the leucine zipper isn’t functioning as a classic
dimerization motif in mitotic spindle regulation. In previous studies, mutations of leucine
residues to large arginine residues within this region may have altered the conformation
of RHAMM protein and thus disrupted binding sites that may or may not overlap the
leucine zipper region. Results presented here demonstrate that site mutating single
leucine residues establish a role for the leucine zipper dimerization motif in directed cell
migration.
Recent work has identified a role of the leucines in the leucine zipper region of RHAMM
in TPX2 interactions and for its proper localization and activation of AURKA (100). The
consequence of TPX2/AURKA mislocalization has been shown to result in abnormal
mitosis, characterized by shortened/compressed mitotic spindles giving rise to mitotic
failure (100, 136). As proper positioning and alignment of the spindle poles relative to
each other determine spindle length (137), it is likely that RHAMM’s role in maintaining
spindle orientation is partially through its interactions with TPX2. Furthermore, TPX2
has functions in mitotic spindle integrity that are independent of AURKA(11) and these
functions may be in part mediated through RHAMM activity. Although it is assumed,
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these studies have not established whether the leucine zipper is functioning as a
dimerization motif in TPX2 interactions or if it is specific to leucine residues or
overlapping binding sites. It is therefore difficult to predict whether our mutations,
L735R or L728A/L735R, will contribute to TPX2 mislocalization and future studies will
need to address this.
Whether TPX2 is in fact regulating the major effect of RHAMM on mitotic spindles, has
yet to be examined. Work in our lab has also shown that RHAMM’s effect on mitotic
spindle assembly is indirectly through MEK1 activity since mutant active MEK1 has the
ability to rescue mitotic defects seen in RHAMM-/- fibroblasts.
Our studies also revealed an important role of the leucine zipper in directed cell motility,
and thus future studies will need to address the role of RHAMM/TPX2 interactions on
cell migration. The role of TPX2 in cell migration is an understudied area of research, but
has been shown to regulate migration and invasion of colon cancer cell lines (138). A
mechanism linking TPX2 and ERK, if any, with regards to mitotic spindle functions and
migration will need to be elucidated. A full understanding of how RHAMM regulates
these cell processes including mitosis and migration can provide insight on RHAMM’s
role during cancer initiation and progression.

Conclusions
Results of this study show that RHAMM directly binds tubulin heterodimers in vitro via a
carboxyl terminal sequence and further, that this interaction is not mediated by the
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leucine zipper dimerization motif. Evidence presented in this study suggests that
disrupting the leucine zipper by site mutating single leucine residues does not affect the
binding of RHAMM to tubulin and importantly has no detectable effects on mitotic
spindle integrity as assessed using the surrogate markers of cell cycle progression, cell
proliferation, and apoptosis. However, ablating the leucine zipper function did aberrantly
increase centrosome number in interphase cells and disrupted directed cell migration,
which is a centrosome function. Our results, combined with previous work, suggest a
model wherein extracellular RHAMM/ERK impacts rate of motility, while intracellular
RHAMM interacts with centrosomes to control directed cell migration (Figure 4.1).

Limitations
Although this study provided data based on using a surrogate approach to assess whether
RHAMM/mitotic spindle interactions were abolished, studies are needed to confirm
direct effects in cell culture. Surrogate markers can provide insight albeit not definite
results. Furthermore, while in vitro studies displayed that point mutations in the leucine
zipper region do not disrupt binding to tubulin heterodimers, in vitro, we need to confirm
it in cell culture. The lack of reliable RHAMM antibodies for immunofluorescence makes
it challenging since expression of GFP tagged-RHAMM in cell lines is difficult.
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Figure 4.1: Proposed model for RHAMM-regulated cell migration
Cell surface RHAMM regulates ERK activation, which impacts rate of cell motility,
while intracellular RHAMM forms interact with centrosome structures and affect polarity
and directed cell migration
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Appendices

Tumor Wet Weight (grams)

A) Experiment 1: Xenograft tumor formation summary
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B) Experiment 2: Xenograft tumor formation summary
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C) Experiment 3: Xenograft tumor formation summary
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Appendix A Wet weights of wildtype and mutant 10T1/2-RHAMMΔ163 xenograft
tumors
10T1/2 RHAMMΔ163 expressing, wildtype or mutant, fibroblasts were subcutaneously
injected in the flank of NSG immune compromised mice and tumor growth was
monitored over 6 weeks. Mice that developed tumors were sacrificed and tumor wet
weights were measured. Three separate experiments were carried out (A), B), and C))
with n=3 mice per cell line injected per experiment. Each bar under a given cell line
represents the wet weight of a single tumor formed from an individual mouse from each
experiment. Lack of bars or less than 3 bars under a given cell line identify that tumors
did not form or that tumors did not form in all experimental mice, respectively. The
differences in tumor weights between cell lines could not be compared as tumor-forming
capabilities varied between experiments. Studies in our lab are currently underway to
investigate the discrepancies in this data.

